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Table
ER positive
Response to first No. of No. with stable
line tamoxifen patients disease on megace
Stable disease 33 21 (64%)
Progression 27 3 (11%)
ER negative
Response to first No. of No. with stable
line tamoxifen patients disease on megace
Stable disease 14 7 (50%)
Progression 19 3 (16%)
Megace appears useful in patients who have had a pre-
vious response to tamoxifen. There is a poor response rate to
megace in patients who have previously failed on tamoxifen.
The concept of stable disease appears a useful clinical
method of identifying hormone sensitive tumours likely to
benefit from further hormone therapy.
Abstracts of Members' Proffered
Papers - Oral Presentations
The use of megace in advanced breast cancer
J.R.F. Robertson, M.R. Williams, D.A.L. Morgan, R.I.
Nicholson & R.W. Blamey
Department of Surgery, City Hospital, Nottingham, UK.
We have treated 163 patients with megestrol acetate (megace,
Bristol-Myers) assessable for response at 6 months by UICC
criteria. They were also assessable for response to prior
tamoxifen therapy. Response and static patients have been
grouped together as stable disease. For patients receiving
megace as second line therapy, stable disease on tamoxifen
was a good predictor of response to megace. Sixty out of 97
patients (62%) stable on tamoxifen were subsequently stable
on megace. Only 11 out of 66 patients (17%) who had
progressed on tamoxifen were stable on megace.
ER status and concentration, available from the primary
tumour in 93 patients, was a good predictor of response to
tamoxifen as first line therapy. Response to second line
megace was predicted better by previous response to tamoxi-
fen than by ER status:
*Enquiries to the ACP Secretariat, Department of Medical Oncol-
ogy, Christie Hospital and Holt Radium Institute, Manchester
M20 9BX, UK.
tFor Abstracts, see pp. 223-254 this issue.
Reprints of these abstracts are not available - Ed.
Mitozantrone as a single agent in advanced breast cancer
J.F.R. Robertson, M.R. Williams, D.A.L. Morgan & R.W.
Blamey
Department of Surgery, City Hospital, Nottingham, UK.
The treatment of patients with metastatic breast cancer is
palliative rather than curative. In treating patients with
chemotherapy, clinicians have to carefully weigh the benefits
against the side effects. We have treated 76 patients with
single agent mitozantrone with an overall objective response
rate at 6 months of 15%. A further 22% had static disease
for a minimum period of 6 months. Side effects were
acceptable. All 76 patients had received at least one hormo-
nal therapy and 30 patients had previously received ifosfa-
mide. Previous ifosfamide therapy gave no indication
whether an individual patient would respond to
mitozantrone.
Adriamycin as a single chemotherapeutic agent in the
treatment of advanced breast cancer has a reported response
rate between 38-50%. The rate of response for mitozantrone
ranges from 4-44% with a reported mean of 17% (Leyden et
al., Aust. N.Z. J. Surg., 54, 21, 1984). Our response rate lies
at the lower end of this range, although with less side effects
than adriamycin at standard dose.
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Doxorubicin concentrations in breast tumours, compared with
concentrations in normal breast tissue from patients
undergoing mastectomy
S. Stallard1, J.G. Morrison', W.D. George2 & S.B. Kaye'
Departments of 1Medical Oncology and 2Surgery, University
of Glasgow, UK.
Chemosensitivity is often assumed to be related to the
concentration of drug achieved in tissue, however little is
known about the relative sensitivities of breast carcinomas
and normal breast tissues to cytotoxic agents. In this study
we have compared doxorubicin (DOX) concentrations in
paired samples of tumour and normal breast from 21
previously untreated patients, undergoing mastectomy. The
relative cellularity of tumour and normal tissue was esti-
mated from the DNA content of both. We have correlated
tissue drug levels with serum pharmacokinetic parameters,
and also with other known prognostic factors for breast
cancer such as ER status and histological grade.
Patients received (25 mg) i.v. DOX, - 1 h before removal
of the breast (actual times 60+ 10min s.d.) and serum
samples were taken at 5, 15, 30, 60 min. Doxorubicin
concentrations from serum and tissue were determined by
HPLC and DNA content by Burton's method.
There was wide variation in intra-tumoral DOX concen-
trations (range 220 ngg-1 to 1,590 ngg-1). Normal tissue
also showed a wide variation (range 81 ng to 1,000 ng). In all
cases except one, tumour levels were higher than normal
tissue levels for a single patient (tumour: normal ratio range
1.27 to 8.30). When DOX was expressed in terms of weight
of DNA the tumour and normal drug concentrations were
similar (tumour to normal ratio range 1.1 to 1.8). Tissue
DOX concentrations (both tumour and normal breast) corre-
lated with peak serum values (P<0.05). These findings
suggest that, although there is interpatient variation in tissue
levels, drug concentrations in tumour and normal breast are
similar in a single patient.
Chemotherapy of advanced breast carcinoma in Africans
R.O. Senbanjo, F.N. Ihekwaba & O.O. Ajayi
Department of Surgery, University College Hospital, Ibadan,
Nigeria, UK.
Nigeria and indeed Africa remains today the greatest reposi-
tory of advanced breast cancer. Some cancer patients from
Africa seek treatment in Europe and America where chemo-
therapy is given using Caucasian standards. Fifty-four Niger-
ians with advanced breast cancer were treated with standard
schedule of cyclophosphamide, methotrexate and 5-fluoro
uracil (CMF) on out-patient basis. The dose of all chemo-
therapy drugs was reduced in any subsequent cycle by 30%
with moderate toxicity (WBC <3,000mm-3; platelet
<100,000mm 3) or 50% with severe toxicity (WBC
<2,000 mm-3; platelet <75,000mm-3). The mean total
dose received was calculated as a percentage of the standard
dose for each patient over a 6 month period.
The patients, aged between 25 and 69 years (mean 47
years) had inoperable Stage III disease (26 patients), Stage
IV disease (10 patients) or recurrent/metastatic disease after
mastectomy (18 patients). Only 2 patients (4%) were able to
receive over 85% of the calculated standard dose, while 43
(80%) received less than 65% of the calculated standard
dose. The maximum tolerance dose in Nigerians is much
lower than in their Caucasian counterparts although compar-
able figures were obtained for objective response rate (47%);
median duration of response (7 months) and median survival
(9 months). Leukopenia (WBC<2,500) occurred in 48%
during the first course and in subsequent courses in an
additional 21% of patients. Three patients (6%) died of
chemotherapy related causes all during the first course. The
normal leucocyte count is lower in Africans and malnutri-
tion, infections and infestations are rampant. The role of
these factors in the poor tolerance of chemotherapy in
Africans requires further investigations.
A direct radioimmunoassay (RIA) for 4-
hydroxyandrostenedione measurement in plasma
J. Khubieh, W. Aherne & J. Chakraborty
Biochemistry Department, University of Surrey, Guildford
GU25XH, Surrey, UK.
4-Hydroxyandrostenedione (4-OHA) is a potent and specific
inhibitor of aromatase which mediates the conversion of
androgens to oestrogens, and has been successfully used for
the treatment of breast cancer. Plasma levels of 4-OHA (0.7-
23.2 ngml-1) have been measured in a Phase II study (Goss
et al., Cancer Res., 46, 4823, 1986) by adapting an RIA for
androstenedione which cross-reacts by 25% with 4-OHA.
We report here the characteristics of an RIA using a specific
antiserum to 4-OHA, and a tritiated label (15.6Cimmol-1)
for direct plasma assay at the low concentrations expected.
The standard curve ranges from 50ngml-1 to 5 ngml-1
with a lower limit of detection of 0.25ngml-1. Inter-assay
variation of a pooled patient sample measurement was 6%
(37.6 ngml - +2.32). Complete recovery of 4-OHA added to
normal female plasma was obtained at concentrations of
1 ngml 1 to 2ngml -1. Analysis of patient samples and
normal plasma enriched with 4-OHA showed that up to
87% of plasma 4-OHA was bound to proteins.
The antiserum cross-reacts with androstenedione, testoster-
one, 3f,-hydroxy-5a androstan-4,16 dione, 4-hydroxy-
oestrone, 4-hydroxy-oestradiol and cortisol by 0.9, 2.4, 0.6,
0.3, 0.5 and 0.3% respectively. RIA of 4-OHA in plasma
samples carried out in conjunction with solvent extraction
and Lipidex 5000 chromatography confirmed that there was
no interference from androstenedione. However, 4-hydroxy-
testosterone (4-OHT), a putative metabolite of 4-OHA,
cross-reacts by 100%. The RIA, will not only be useful for
pharmacokinetic studies of 4-OHA, but, combined with
Lipidex 5000, will provide a means of determining the extent
and time course of metabolism to 4-OHT.
HMFG2 expression in primary ovarian cancer, relationship
to tumour differentiation and survival
S.G. Allan, F.G. Hay, L.W. Adams & R.C.F. Leonard
Imperial Cancer Research Fund Medical Oncology Unit,
Department of Clinical Oncology, Western General Hospital,
Edinburgh, UK.
The HMFG2 antigen is variably expressed and may be of
prognostic significance in cancers of the lung and breast. It
is also expressed variably on the cell surface of ovarian
cancer primary tumours and is shed into the serum, a
potential target for disease monitoring and therapy. Careful
evaluation of the immunoreactivity among the histological
subtypes of ovarian cancer is thus important and may
provide prognostic information. We have looked at HMFG2
expression in a variety of formalin-fixed primary tumours of
ovarian epithelial origin and related antigen expression to
differentiation and to survival. Using a standard PAP tech-
nique tissue sections were assessed and scored by two
observers for extent of staining, 0, <50% and >50%
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Serous Mucinous Endometrioid
WDa PDb WDa PDb WDa PDb Clear cell
0 1 0 2 0 0 0 0
<50 1 3 3 0 3 1 4
>50 3 10 4 1 2 0 0
aWD=Well differentiated. bPD=Poorly differentiated.
The majority of ovarian cancer primaries exhibit HMFG2
but unlike Ward et al., (Cancer, 60, 787, 1987) the series
shows that poorly differentiated serous carcinomas exhibits
marked expression of HMFG2 in contrast to the other
serous types. Other histopathological groups do not show
such a consistent pattern. Within a single specimen hetero-
geneity of staining was seen. Regardless of therapy, the
survival of patients who express HMFG2 strongly (>50%)
was worse than those who expressed it poorly (<50%)
respective survival times being 11 months and 16 months
(P=0.01, Mann-Whitney U). Further data accrual will be
required to verify this finding.
The effect of LHRH agonist, zoladex, on ovarian histology
J.F.R. Robertson, K. Williamson, I.O. Ellis, R.I.
Nicholson & R.W. Blamey
Department of Surgery, City Hospital, Nottingham, UK.
In premenopausal women with advanced breast cancer the
luteinising hormone releasing hormone (LHRH) zoladex
produces response rates similar to surgical oophorectomy.
There have been proposals both to use zoladex as adjuvant
therapy and in benign disease: irreversible ovarian suppres-
sion would be an unwanted side effect in these patients. We
have looked at the histological changes in the ovaries of
patients with advanced breast cancer treated by zoladex.
In a phase I clinical trial of zoladex as first line hormonal
therapy in premenopausal women with advanced breast
cancer, patients on progression of their disease underwent
surgical oophorectomy. The histology of 39 ovaries from 23
women treated with zoladex (Zx) has been compared to 68
ovaries from 34 patients who underwent surgical oophorec-
tomy as primary therapy (Ox).
Histologically both the Zx and Ox groups show similar
follicular phase development. Follicular cysts were seen more
often in the ovaries of Zx treated patients than in the Ox
patients (P<0.05). Corpus lutea were seen more often in
the ovaries of Ox patients than in the Zx patients (P<0.01).
Zoladex appears to arrest development of follicles with
formation of follicular cysts. Despite low FSH levels
folliculogenesis was not inhibited.
Oestrogen and progesterone receptors in ovarian cancer
M. Harding', S. Cowan2, L. Cassidy3, H. Kitchener3 & R.
Leake2
Departments of IMedical Oncology, 2Biochemistry and
3Gynaecology, University of Glasgow, UK.
The prognostic significance of steroid receptors in breast
cancer is well recognised. To determine whether expression
of receptors is a biological marker of less aggressive disease
in gynaecological cancer, quantitation of oestrogen (ER) and
progesterone (PR) receptors has been carried out over the
last 4 years. Soluble and nuclear receptor levels were deter-
mined by Scatchard analysis: tissue samples were defined as
positive if soluble ER and/or PR levels exceeded
10fmolmg-1 protein with nuclear levels >150fmolmg-
DNA.
The majority of benign ovarian cysts (14/15) and border-
line malignant tumours (2/2) were ER- PR-: both (2/2)
granulosa cell tumours were ER+ PR+. Of the 66 samples
from patients with non-pretreated epithelial ovarian cancer,
18 were ER+ PR+ (27%), 15 were ER+ PR-, 5 were ER-
PR+ and 28 were ER- PR- (42%); approximately 10% of
each subgroup were premenopausal. FIGO Stage I and II
tumours were more commonly PR+ (10/23) than PR- (4/43)
but there was no association between early stage and ER
status (6/33 ER+ vs. 8/33 ER-).
Survival of patients with advanced disease (FIGO Stages
III or IV) indicates that expression of steroid receptors may
be of prognostic significance though data are preliminary.
Median survival (in months) according to receptor status
was:
The use of verapamil to overcome drug resistance in
myeloma
M.E. Gore, P.J. Selby, B. Millar, J. Maitland & T.J.
McElwain
Institute of Cancer Research and Royal Marsden Hospital,
Downs Road, Sutton, Surrey, UK.
There is considerable experimental evidence that verapamil
can overcome adriamycin resistance in a variety of experi-
mental tumour models. Following a suggestion made by
Durie and colleagues that this phenomenon might be applied
to patients with myeloma, we have conducted a study on 7
myeloma patients with acquired or primary resistance to the
VAMP regimen (vincristine 0.4mg daily, adriamycin
9mgm-2 both by continuous infusion for 4 days, methyl-
prednisolone 1 gm-2 IV orally daily for 5 days repeated
every 3 weeks). Four patients were treated with VAMP to a
plateau phase i.e. after achieving the maximum reduction in
paraprotein no further response to VAMP was seen. Three
patients had primary VAMP-resistant disease. These 7
patients were all treated with verapamil (10mgday-1 by
continous infusion for 5 days) together with further treat-
ments with the VAMP regimen. In 4 out of 7 patients the
treatment produced further reductions in the paraprotein
levels of >25%. In 2 of these patients, the paraprotein fell
by >50% and in one case the paraprotein became unmeas-
urable. Two of the responders to initial observations support
the hypothesis that verapamil can overcome some of the
mechanisms of resistance to adriamycin and vincristine-
containing regimens in patients suffering from myeloma.
Further studies to elucidate its precise role in the manage-
ment of myeloma patients treated on this and similar
schedules are indicated.
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Phase I study of recombinant DNA granulocyte-macrophage
colony stimulating factor (rGM-CSF)
W.P. Steward', R. Austin2, J.H. Scarffe', D. Crowther',
N. Thatcher', G. Morgenstern2 & P. Loynds3
1CRC Department of Medical Oncology, 2Department of
Haematology, Christie Hospital, Wilmslow Road,
Manchester M209BX; 3Schering Corporation, Herts, UK.
Recombinant DNA granulocyte-macrophage colony stimu-
lating factor (rGM-CSF) (Schering Corporation, New Jer-
sey) was administered as i.v. infusions over 30 min to
patients (pts) with advanced progressive neoplasms. The
schedule was as follows: 10 days of daily infusions, 10 days
without GM-CSF, 10 days of daily infusions and finally 20
days of alternate day infusions. Regular routine haematolo-
gical and biochemical investigations were performed and
blood was taken to assess pharmacokinetics and neutralising
antibodies to GM-CSF. Bone marrows were taken during
treatment to obtain GM-CFC and mixed population assays.
The study design was for 3 pts to be entered at each of the
following dose levels: 0.3, 1, 3, 10, 30, 60 ugkg- 1 body
weight. The study endpoint was a maximum tolerated dose
(MTD) resulting in a WBC >50,000 mm-3 or platelets
>600,000 in 66% of pts (6 pts to be entered at the MTD).
Fifteen pts have entered this study to date, 3 at each dose
level to 30/,gkg-1. No significant alteration of any haema-
tological parameters was seen with 0.3 or 1 pgkg-1. The
mean total WBC count ( x 1091-1) over the first 10 days of
GM-CSF rose from 11 to 14 at 3 pgkg-1, 8 to 23 at
10pgkg-1 and 7 to 27 at 30pgkg-1. No significant differ-
ence in the granulocyte:monocyte ratio occurred, but an
eosinophil was seen (up to 12% total WBC count) at dose
levels above 3 pgkg-1. The magnitude of the rise in WBC
count appears to be greater during the second phase of daily
infusions. There was a rapid fall of WBC count to pre-
treatment levels after the cessation of GM-CSF (mean 48 h).
Side effects included transient pyrexia after the first two
infusions of GM-CSF and bone pains (predominantly lower
vertebrae) which were severe and required analgesia in 2
patients receiving 30 pgkg-1 and one receiving 10 pgkg -I
Further patients are being entered at a dose of 60pgkg- 1
and this is anticipated to be the MTD. No antibodies to
GM-CSF have been detected in 6 patients tested to date.
Phase I study of the anthrapyrazole CI-941 with
pharmacokinetically guided dose escalation
M.A. Graham, B.J. Foster, D.R. Newell, L.A. Gumbrell &
A.H. Calvert
Drug Development Section, Institute of Cancer Research,
Sutton, Surrey, UK.
CI-941 is a novel DNA binding drug which displays equiva-
lent or superior antitumor activity to doxorubicin in experi-
mental systems yet does not undergo metabolic reduction in
vitro and hence is unlikely to cause free radical mediated
tissue damage in vivo. The MTD and LD50 of CI-941 in
mice (i.v. bolus dose) were 45 and 60mgm2, respectively,
with a plasma concentration vs. time AUC at the MTD of
110 ,M -min. The pharmacokinetics of CI-941 were linear in
mice over the dose range 4.5-45mgm-2 and the plasma
protein binding in human and mouse plasma was similar
(80-90%). The dose limiting toxicity in mice was leukopenia.
In a phase I study of CI-941 given as an i.v. bolus dose once
every 3 weeks 14 patients have received a total of 23
evaluable courses. The starting dose was 5 mgm-2 with a
target plasma AUC of 110 pM min. Wide variation in AUC
at 5 mgm-2 (23, 17, 54 pM -min) cautioned against rapid
escalation and hence 5 mgm-2 dose increments were
employed up to 30mg.m2 Pharmacokinetic monitoring has
been completed on 10 patients following 14 courses at doses
up to 25mgmg-2 CI-941 plasma clearance is triphasic with
t1/2 values of7.5+ 1.8 min, 69+30 min and 19+7 h. The mean
total plasma clearance of CI-941 was rapid
(436 ml min-m 2), however, over this dose range consider-
able variation was found (coefficient variation 47%). Varia-
tion in CI-941 clearance was not explained by pretreatment
renal, hepatic, or cardiac function. In 4 patients who
received 2 courses of CI-941 the interpatient variation in
clearance was larger than the intrapatient variation. At
25 mgm-2 the AUC was 81, 89 and 129 1iM min indicating
that the target AUC should be achieved at 30 mg.m2 In
agreement with this prediction leukopenia has been observed:
25mgm-2 2/6 WHO grade 1, 4/6 grade 2; 30mgm-2 1/1
grade 1. Other toxicities at 25 mgm-2 include nausea and
vomiting; 3/6 grade 1, 1/6 grade 2, 1/6 grade 3 and
mucositis; 1/6 grade 1, 3/6 grade 2. This study has shown
that although pharmacokinetics were of value in guiding
dose escalation the interpatient variability found with CI-941
precluded the use of dose increments dictated solely by
pharmacokinetics.
Chronopharmacology of carboplatin
D.J. Kerr, C. Lewis, B.O'Neil, N. Lawson, R. Blackie,
E.M. Rankin & S.B. Kaye
Department of Medical Oncology, University of Glasgow,
UK.
Depending on the time of administration, a fixed dose of
drug may be toxic or therapeutic. Circadian (about daily)
stage dependence has been demonstrated in animal models
for a number of commonly used cytotoxic agents and there
is increasing clinical awareness of the importance of timing
drug delivery. We treated 8 patients with advanced ovarian
cancer (stages II and IV) with carboplatin (400mgm-2) at
0600 or 1800 on successive courses, in random order. Plasma
ultrafiltrate and urinary carboplatin concentrations were
measured using a sensitive and specific HPLC assay and full
blood count was estimated weekly.
Peak plasma Urinary
core AUC excretion
Time (,igml 1) (ugm-l1h) (mg24h-1)
0600 42.3+21 92+22 174+36
1800 47.3 + 16 113 +28 58+28
Time WBC Platelets
0600 3.0+ 1.0 95,000+23,000
1800 3.7+0.9 180,000+ 56,000
It is clear from this data that the time of administration of
carboplatin has a significant effect on the pharmacokinetics
of the drug and the ensuing degree of myelosuppression.
Predictors of etoposide pharmacokinetics in man
P.I. Clark, S.P. Joel, S. Houston, W.M. Gregory
& M.L. Slevin
ICRF Department of Medical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
Pharmacokinetics (PK) of 101 patients consecutively treated
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for factors predictive of etoposide PK. The areas under the
plasma concentration versus time curve (AUC) have been
standardised to a dose of 100mgm-2. Mean values +s.d. of
elimination half-life (t1/2) were 6.5 + 1.9 h,
AUC 105 + 31 pgml-1 h, volume of distribution (Vd)
9.4+3.0m-2 and plasma clearance (C1)
17.2+5.5 mlmin m 2. Univariate analysis showed signifi-
cant correlations between AUC and both plasma creatinine
(P) (r=0.50, P<0.001) and logP (r=0.50, P<0.001).
Multivariate linear regression analysis showed no further
significant correlations of either AUC or Cl with age,
albumin, bilirubin, alkaline phosphatase (ALP), aspartate
transaminase or gamma-glutamyl transferase (GGT).
Patients with renal and hepatic impairment were examined
separately and compared to those with normal function.
Eighty-three patients had P< 130 pmolI -1, ALP<200 IU1 -1
and GGT<l00IUI-1, and for these, mean +s.d. were t,/2
6.5+ 1.6, AUC 104+25, Vd 9.4+3.1 and C1 17.0+4.4. Seven
patients had renal impairment with P> 130,mol -1 and had
significantly altered t1/2 9.2+2.9 (P=0.004, Mann-Whitney),
AUC 163+36 (P=0.0002), Cl 10.7+2.4 (P=0.0002), Cl
10.7+2.4 (P=0.0002) but not Vd 8.1 + 1.1 (P=0.25). Eleven
patients had normal renal function but either ALP>200 or
GGT> 100 or both, and had significantly changed t1/2
4.8+1.6 (P=0.004), AUC 79+22 (P=0.004), Cl 12.1+8.3
(P=0.004) but not Vd 9.8+2.8- (P=0.25). In one patient
with obstructive jaundice, PK returned to normal after
resolution of porta hepatis lymphadenopathy. Etoposide may
need dosage reduction in renal impairment. Further studies
of PK and drug metabolism are necessary in patients with
hepatic dysfunction before recommending increasing dosage
in such patients.
Sclerosis of lytic bone metastases from breast cancer in
response to 3-aminohydroxypropylidene-1,1-biphosphonate
(APD)
A.R. Morton1, G.V. Pillai2, J.A. Cantrill2, D.C. Anderson3
& A. Howell1
1CRC Department of Medical Oncology, Christie Hospital,
Manchester; and University Departments of 2Pharmacy and
3Medicine, Hope Hospital, Salford, UK.
The affect of APD was assessed in 16 patients with advanced
endocrine unresponsive breast cancer metastatic to bone.
30mg of APD was given as a 2h infusion weekly for 4
weeks and 2 weekly for 6 months or until disease progres-
sion. Pain was assessed using a linear analogue scale. The
effect of APD on bone tumour was measured by urinary
calcium/creatinine (Ca/Cr) ratio and by hydroxyproline/
creatinine (OHPr/Cr) ratios and serum oesteocalcin. The
effect on the tumour was estimated by serial radiographs and
monthly measurements of CEA and Cal 5.3. Radiological
evidence of sclerosis of lytic metastases was seen in 4
patients and the disease remained stable for the 6 months of
the study in a further 4 patients. Disease progressed within 6
months in 8 patients. Pain was significantly decreased by
treatment (P<0.01). There was a significant decline of Ca/Cr
ratio in all patients (P<0.001); OHPr/Cr and osteocalcin
remained stable. CEA and Ca 15.3 fell in parallel in 3
patients (2PR, 1 stable). No significant side-effects of treat-
ment were seen. We conclude that APD has apparent
'antitumour' activity and gives partial relief of bone pain.
Further studies of APD in combination with standard
therapy are warranted.
Mitomycin, ifosfamide and cisplatin in non-small cell lung
cancer
M.H. Cullen', A.D. Chetiyawardanat, R. Joshi2
& C.M. Woodroffe1
IQueen Elizabeth Hospital, Birmingham; and 2Manor
Hospital, Walsall, UK.
Mitomycin, ifosfamide and cisplatin are three of the most
active single agents in the chemotherapy of non-small cell
lung cancer. We have combined them in a 24h schedule
('MIC') for a phase 2 study in patients with inoperable non-
small cell lung cancer. The regime consists of: mitomycin
6mgm-2 i.v. bolus, ifosfamide 3 gm-2 i.v. infusion over 3h
and cisplatin 50mgm-2 i.v. infusion over 1 h. Mesna is
given with the ifosfamide infusion at a dose of 1 gm-2 and a
further 500mgm-2 bolus is given 3 h later followed by a 6 h
infusion (500 mgm 2). The anti-emetic regime consists of
lorazepam 2 mgm-2 dexamethasone 8 mgm-2 and metoclo-
pramide 1 mgkg-1 i.v. 30 min prior to chemotherapy, metoc-
lopramide 9mgkg-1 over 24h and further doses of
dexamethasone 4mgm-2 i.v. 4 hourly. Fifty-four ambula-
tory (WHO performance status 0, 1 or 2) patients with
inoperable limited (LD) or extensive stage (ED) disease have
entered this study, and 44 are evaluable for response.
Eighteen patients have achieved partial remission (41%) and
6 have achieved complete remission (14%) as assessed radio-
logically. The overall response rate is thus 55%. There have
been 19/28 responses in LD (68%) and 5/16 in ED (31%).
Sixteen patients have experienced an improvement in WHO
performance status rating. Although well tolerated in the
majority of patients, the principal toxicity has been vomiting
which was severe (WHO 3/4) in 9 patients. There has been
one treatment related death. MIC is clearly among the most
active combinations in non-small cell lung cancer and will
now be tested in a randomized trial against no
chemotherapy.
Transforming growth factor alpha (TGFx) and epidermal
growth factor (EGF) in tumour and urine of breast cancer
patients
A. Howell1, H. Anderson1, H. Gregory2, C. Thomas2,
I. Willshire2 & J. Young2
'Department of Medical Oncology, Christie Hospital,
Manchester; and 2ICI Pharmaceuticals Division, Alderley
Park, Macclesfield, UK.
Extracts of breast tumours (n= 15) and of urine of breast
cancer patients and age match controls were subjected to
separation by high performance liquid chromotography.
Fractions were evaluated by mitogenic activity using 3T3
cells, colony formation using NRK cells and by specific
immunoassays for EGF and TGFoa. The system was cali-
brated using pure biosynthetic growth factors. Concen-
trations of TGFcx were similar in 5 oestrogen and
progesterone receptor positive tumours and 5 receptor nega-
tive tumours. In 5 tumours removed from patients on
tamoxifen TGFa levels were greatly reduced compared- with
the other two groups. No EGF was detectable in tumours.
Both TGFa and EGF were present in similar concentrations
in the urine of breast cancer patients and controls. We
conclude that tumours do not produce EGF, but produce
TGFoa which is suppressable by tamoxifen. Similar concen-
trations of both growth factors in patients and controls
suggest that the major source of TGFx is from sites other
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Enzyme activity in concentration of serum placental alkaline,
phosphatase (PLAP) in monitoring patients with ovarian
cancer
A. Bowman', J. Fisken2, J.E. Roulston2 &
R.C.F. Leonard'
'University Department of Clinical Oncology, Western
General Hospital, Edinburgh; and 2University Department of
Clinical Chemistry, Edinburgh, UK.
One hundred and fourteen patients with ovarian carcinoma
(FIGO stage I (12), II (10), III (69), IV (22) at presentation)
had 424 serum samples assayed for the presence of PLAP
using the monoclonal antibody H17E2 in a novel immuno-
radiometric assay which measures simultaneously PLAP
activity (A) and concentration (C). Normal ranges were
defined on 387 blood donor samples with known smoking
history and patients' borderline results disregarded. Corre-
lating serum PLAP with surgical, clinial and radiological
disease status, overall sensitivity of PLAPA was 61.7% and
C 35.3%, specificity of A was 53.7% and C 74.6% and
accuracy of A was 60% and C 49%. Serial levels correlated
with clinical disease course in less than 50% of patients. In
21 patients with pathological results available from second-
look laparotomy, false positive results for both A and C
were noted.
CA 125 PLAPA PLAPC
+ ve -ve + ve -ve + ve -ve
Pathological CR 0 11 8 3 2 6
Pathological PR 4 6 5 5 2 6
This rigorous clinical test illustrates the severe limitations
on the value of PLAP as the sole marker of disease activity
in carcinoma of the ovary.
c-myc oncogene expression and cell growth parameters in the
evolution of colorectal carcinoma
P. Johnston', M. O'Brien', P. Dervan', B. Guillick2
& D.N. Carney'
'Mater Hospital, Dublin 7, Ireland; and 2Institute of Cancer
Research, London, UK.
Using an immunohistochemical technique and radiolabelled
oncogene probe hybridization we have evaluated the expres-
sion of c-myc oncogene and Ki-67 nuclear antigen in colo-
rectal carcinomas, adenomas and normal colonic epithelium.
Results were correlated with histological grade and Dukes'
stage. Cytoplasmic expression of c-myc was detected in 40/44
carcinomas, 25/28 adenomas and in the crypts of all 10
normal colonic mucosas. In the normal mucosas c-myc
expression was noted throughout the intestinal tract with
staining intensity similar in both the surface epithelial cells
and the basal areas of the crypts. Heterogeneity in cyto-
plasmic staining was present in many adenomas and carcino-
mas. c-myc gene amplification was detected in only 1 of 20
tumours analysed and in no adenomas. No correlation was
noted between c-myc expression, histological grade or Dukes'
stage. Ki-67 nuclear expression was found in all specimens
examined. The percentage of Ki-67 positive nuclei varied
among the specimen type, 19-42% in proliferative zones of
normal crypts, 20-67% in adenomas and 20-87% in adeno-
carcinomas. Ki-67 expression was confined to the prolifer-
ative zone of the crypt while in carcinomas and adenomas
diffuse staining was noted. No correlation was noted
between histological grade and Dukes' stage. These data
suggest that Ki-67 antigen expression correlates with disease
evolution of colorectal adenomas and carcinomas. However
no correlation was noted between c-myc expression and the
evolution from normal mucosa to adenoma and
adenocarcinoma.
Molecular studies of multiple endocrine neoplasia, Type 2a
(MEN2a) and clinical implications
B.A.J. Ponder', C.G.P. Mathew', D.F. Easton', K. Chin',
B. Smith', M.A. Ponder', H. Telenius', K. Nakamura3,
T. Cummings4, H. Sobols and G. Lenoirs
Sections of 'Human Cancer Genetics and 2Epidemiology,
Institute Cancer Research, Sutton, UK; 3Howard Hughes
Institute, Salt Lake City; 4Tufts New England Medical
Center, Boston, USA; and 5IARC, Lyon, France.
MEN 2a is an autosomal dominant inherited cancer syn-
drome comprising medullary thyroid carcinoma (MTC:
arises from thyroid 'C' cells) and phaeochromotocytomas.
Family members can be screened by regular measurement of
calcitonin after a provocative stimulus, and by measurement
of catecholamines. A genetic marker would eliminate from
screening the 50% of family members not at risk, and would
be the first step towards elucidating the gene defect and its
mechanism. We have mapped the MEN 2a locus to chromo-
some 10 by genetic linkage using DNA polymorphisms
(Mathew et al., Nature, 328, 527, 1987). Currently we have
identified 2 DNA markers which are close to the MEN 2a
locus, IRBP/RBP3 (LOD score Z 12.78, 0=0.03, 95% upper
CL 0.09) and MCT 50 (Z 7.10, 0=0.03). Each of 13
informative families tested shows evidence of linkage, but no
data are yet available for families with MTC only, nor
MEN 2b. The progress of this work and the potential clinical
use of current markers will be presented.
Analysis of MEN 2 tumours with chromosome 1O probes
has so far shown no allele loss in 16 informative cases. It is,
however, premature to conclude that the double recessive
mechanism described for retinoblastoma and other inherited
tumours does not also operate in MEN2.
Inherited predisposition to breast cancer
B.A.J. Ponder', D.F. Easton2, K. Anderson2 & J. Peto2
Sections of 'Human Cancer Genetics and 2Epidemiology,
Institute of Cancer Research, Sutton, Surrey SM25PX, UK.
There is no proof that familial clustering of breast cancer
has an inherited rather than an environmental basis. Proof
will only come from the identification of a genetic marker
which segregates with breast cancer in the families. Such a
marker would improve the recognition of individuals at risk.
It would also be a first step to unravelling the mechanism of
predisposition, which might lead to the identification of the
important carcinogens and to rational efforts at prevention
or treatment. The search for the gene presents problems.
One approach is to identify pairs of affected siblings with
premenopausal disease and to obtain blood for linkage
studies using DNA markers. On the basis of random segre-
gation, sisters should share both alleles at any locus by
inheritance from their parents with a probability of 1:44,
neither allele 1:4, and one or other allele 2:4. The presence
of a 'breast cancer gene' will distort this random inheritance
pattern for a DNA marker close to the disease locus. The
advantage of this approach over 'classical' linkage is that it
avoids the need to specify (1) a dominant or recessive model,
or (2) the penetrance, and (3) it can accommodate the
problem of phenocopies. Our analysis of a large population-
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themselves under 50 years, of cases diagnosed below 50
years, is increased 3.5-fold. If this increased risk were due to
a single dominant gene, with 150-200 highly polymorphic
DNA markers at 20 cM intervals over the genome, this gene
could be detected by linkage using 80 sib pairs, while a
recessive gene would require at most 30 pairs. If the effect
were due to two dominant genes, in the worst case up to 200
pairs may be required.
Ototoxicity of cis-platinum
R. Skinner1, A.D.J. Pearson', H.A. Amineddine1,
D.B. Mathias' & A.W. Craft'
'Department of Child Health, University of Newcastle upon
Tyne; and 2Ear, Nose and Throat Department, Freeman
Hospital, Newcastle upon Tyne, UK.
Cis-platinum is an important drug in the treatment of
childhood malignancy. However, it has a number of adverse
effects, one of which is ototoxicity. To determine the extent
and reversibility of hearing damage in children treated with
cis-platinum, 22 patients had serial audiograms. Their ages
at start of treatment ranged from 7 to 19 years, with a mean
of 13 years and they received a median cumulative dose of
cis-platinum of 543 mg m 2 (range 312 to 1072mgm-2) for
oesteogenic sarcoma (11), primitive neuroectodermal tumour
(5), rhabdomyosarcoma (3), neuroblastoma (2) and
dysgerminoma (1).
Maximum hearing loss was greater at high frequencies
with a median loss of 12.5 decibels (dB) (range 2.5-32.5) at
1,000 Hz, 10.0dB (range 0-62.5dB) at 2,000 Hz, 31.25 dB
(range 7.5-95dB) at 4,000Hz, and 70.0dB (range 17.5-
95dB) at 8,000 Hz (P<0.0001). There was no significant
difference in the severity of hearing loss between right and
left ears.
There was no significant correlation between the severity
of hearing loss and the number of days of other ototoxic
treatment, the total dose and the number of courses of cis-
platinum, and the age at the start of treatment. There was
no significant difference in hearing loss between children
receiving high dose (200mgm 2) and those receiving
conventional dose (75-125 mgm-2) cis-platinum.
Five of 7 children who had follow-up audiometry
continued for more than a year after the end of treatment
showed some reversibility of hearing loss (defined as an
improvement of 15 dB or greater) in at least one ear.
This study demonstrates that ototoxicity is a significant
adverse effect of cis-platinum, but further follow-up is
needed to determine how much recovery may occur. No
increase in toxicity occurred with use of high dose
cis-platinum.
Persistent renal damage after treatment with cis-platinum for
childhood malignancies
A.L. Brunetto1, A.D.J. Pearson1, L. Price1,
H.A. Aminnedinel, W. Sheldon1 & A.W. Craft1
Departments of 'Child Health and 2Clinical Biochemistry,
University of Newcastle upon Tyne, UK.
It is recognised that cis-platinum may cause acute renal
damage with a reduction in the glomerular filtration rate as
well as renal tubular dysfunction. As there is now an
increasing number of survivors of childhood cancer it is
important to determine the late effects of therapy. Therefore
a group of children who had completed therapy, which
included cis-platinum, have been studied to determine the
extent of renal damage which persists after cessation of
therapy.
Twenty-one children (12 males) who had received cis-
platinum between 0.3 and 5.6 years previously for oesteo-
genic sarcoma (12), rhabdomyosarcoma (13), yolk sac
tumour (3), neuroblastoma (2) and primitive neuroecto-
dermal tumour had their tubular function investigated and
glomerular filtration rate (GFR) measured. GFR was deter-
mined by the disappearance from the plasma of 51Cr EDTA.
Fifteen patients had a serum magnesium (Mg) concen-
tration below the reference range. In these patients the
urinary excretion of Mg was inappropriately high as re-
flected by a reduced tubular absorption of Mg. Compared to
control children these children had a significantly lower Mg
concentration (P=0.014), lower tubular reabsorption of Mg
(P=0.09) and lower tubular reabsorption of phosphate
(P=0.06). No other abnormalities of renal tubular function
were detected. The median GFR for the group was 89 with a
range of 44-125mlmin-1 1.73 m2. The serum Mg concent-
ration, an index of tubular damage, was related to the child's
age, time since completion of chemotherapy, sex, disease,
and amount of gentamycin that the child had been pres-
cribed. Those patients who had received more gentamycin
tended to have a lower serum Mg concentration (P=0.07).
However, there was no relationship between time since
completion of therapy with serum Mg concentration. This
study suggests that renal damage persists in the survivors of
childhood cancer treated with cis-platinum. This dysfunction
is manifested by low serum Mg concentrations and a reduc-
tion of GFR. Early results of follow up studies suggest that
hypomagnesaemia may persist in some children while GFR
may recover.
Gut damage during the treatment of childhood acute
lymphoblastic leukaemia
A.L. Brunetto1, A.D.J. Pearson1, L. Price1, M.F. Laker2
& A.W. Craft1
Departments of 1Child Health and 2Clinical Biochemistry,
University of Newcastle upon Tyne, UK.
Gut toxicity in patients receiving treatment for childhood
acute lymphoblastic leukaemia (ALL) is assuming greater
importance as new intensive strategies are being used. Recent
retrospective reviews show that following consolidation ther-
apy of ALL 38% of patients develop gastrointestinal toxicity
and 25% of these develop persistent intestinal damage. At
present it is impossible to predict prior to therapy which
children will develop these complications. In an attempt to
identify those children at greatest risk of gut toxicity a
cohort of children undergoing intensive therapy for child-
hood ALL have been studied sequentially. Small intestinal
mucosal function has been assessed by a novel intestinal
permeability test. Three non-metabolised sugar markers were
administered in a oral solution of 696 mOsmkg-I containing
4mgm 2 mannitol (M), 4mgm-2 lactulose (L) and
1.6 mgm-2 of 3-0-methyl-glucose (MG). The percentage of
the amount ingested that was excreted in a 5 h urine
collection was measured. M and L passively permeate the
small bowel mucosa while MG is actively absorbed. Fifty
normal children excreted a mean of 0.29% (s.d.=0.1) of L,
42.8% (s.d.=10.7) of MG and 16.3% (s.d.=4.1) of M.
Children with ALL were studied prior to and weekly on 5
occasions after intensification therapy. Two weeks after
chemotherapy M, MG and L absorption was impaired
compared to controls and values before consolidation
(P=0.02 and P=0.05). This was followed by gradual reco-
very which reached normal levels by 5 weeks in the majority
of children. However in some children recovery of sugar
permeation did not occur. Longitudinal studies revealed that
these children developed persistent enteropathy with
malabsorption.
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nutritional characteristics of those children who developed
gut toxicity. By these means it may be possible to identify
those children at greatest risk of gut damage and to develop
methods of intervention to prevent toxicity.
Evaluation of simultaneous four-parameter flow cytometry
for the screening of samples from the uterine cervix
D.C. Davies1, R.L. Adams1, M. Driver2 & D.E.H. Tee1
Departments of 'Immunology and 2Morbid Anatomy
(Cytology), King's College School of Medicine and
Dentistry, London SE58RX, UK.
The purpose of this study is to investigate the role of
multiparametric flow cytometry in the identification of the
normal population in a cervical screening programme. Using
samples from normal and at-risk patients we are simul-
taneously analysing DNA content, cell markers, cell volume
and wide angle light scatter.
A fixation regime has been established allowing staining of
nuclear DNA by propidium iodide without removal or
alteration of the cell surface and without a change in cell
volume. A previous immunohistochemical study, using an
antibody to the transferrin receptor, showed positive staining
with the majority of tumours and severe dysplasias and the
complete absence of staining with normal epithelia suggest-
ing that this antibody may distinguish between normal and
neoplastic cells (Lloyd et al., J. Clin. Path., 34, 131, 1984).
This antibody is now being used in flow cytometry although
other markers are being investigated.
The most effective combination of parameters giving rise
to no false negative results is being established and this
combination will be used to identify normal specimens. Data
from 2,000 cervical samples will be reported comparing flow
cytometry with routine cytology.
Application of multiparametric flow analysis as a primary
screening procedure will drastically reduce the labour content
associated with the examination of normal smears which
form at least 70% of the samples processed by most routine
cytology laboratories.
Urinary ifosfamide metabolite profile after oral and
intravenous administration
H.L. Roberts', M.J. Lind2, N. Thatcher2 & J.R. Idle1
'Department of Pharmacology, St Mary's Hospital Medical
School, London W2JPG; and 2Department of Medical
Oncology, Christie Hospital, Manchester M209BX, UK.
Quantitation of the metabolites of oxazaphosphorine drugs
such as ifosfamide (IF) is important in understanding both
the efficacy and toxicity of the drug in individual patients.
IF and its principal metabolites were determined by high-
performance thin layer chromatography-densitometry
(HPTLC-PD) in 0-24 h urines from 18 NSCLC patients who
had been given IF (1.5 gm 2) either orally or intravenously.
On HPTLC-PD, Rf values for the various metabolites
were: IF (0.70), the two dechloroethyl metabolites (0.47),
carboxyifosfamide (0.33), 2-chloroethylamine (0.10) and iso-
phosphoramide mustard (0.02). At high concentration it was
sometimes difficult to separate these last two alkylating
metabolites; they were thus estimated conjointly.
Percent dose eliminated (mean ± s.d.) after iv. and p.o.
administration respectively for each compound was: IF
(1.9+1.5, 4.1+2.1), dechloroethyl metabolites (2.1 + 1.2,
6.4+3.8), carboxyifosfamide (0.6+0.4, 6.0+ 10.0;), 2-chloro-
ethylamine plus isophosphoramide mustard (0.2+0.5,
5.3±6.2), total recovery ofmetabolites (2.8+1.5, 17.8+14.0).
HPTLC-PD presents a novel means of determining the
urinary metabolites of ifosfamide. Production and excretion
of both the detoxicated and activated metabolites are
increased over 6-fold after p.o. compared with i.v.
administration.
These data may be interpreted as the result of a significant
first-pass metabolism of IF, although this requires further
investigation. Since the cytotoxic metabolites are increased
over 20-fold after p.o. administration, this has clear impli-
cations for the use of oral IF in cancer chemotherapy.
A new approach to rIL-2 treatment in malignant melanoma
- Preliminary analysis of the immunological response in
relation to clinical outcome
A.K. Ghoshl, H. Dazzi2, N. Thatcher2 & M. Moore1
'Paterson Institute for Cancer Research and 2Department of
Medical Oncology, Christie Hospital, Manchester M20 9BX,
UK.
Interleukin 2 (IL-2) is a T cell growth factor and essential for
the induction and growth of lymphokine activated killer
(LAK) cells, a phenotypically heterogeneous effector popula-
tion, derived largely from natural killer (NK) precursors
(CD3- CD16+). Adoptive immunotherapy where LAK cells
were given in conjunction with IL-2 has resulted in an
increased response rate compared to IL-2 alone but treat-
ment toxicity was high (Rosenberg et al., N. Engl. J. Med.,
316, 899, 1987).
To avoid multiple leukophoresis for in vitro generation of
LAK cells and to reduce toxicity, recombinant IL2 (rIL-2)
was given as a first dose via an intra arterial catheter into
the spleen, followed by 4 i.v. doses on alternate days. A total
of 3 courses were planned at 3 week intervals. The maximum
tolerated single dose was 11 x 106 CetusUUm-2. Thirty
patients with progressive metastatic malignant melanoma
entered the study; in 4, treatment is still ongoing. Four
patients showed a PR, 5 have stable disease.
The PBMC of all patients tested contained LAK pre-
cursors estimated by in vitro rIL2 induction of cytotoxicity
against NK-sensitive (K562) and NK resistant, LAK-
sensitive (MEL 1) targets. After in vivo administration, the
proportion of IL-2 receptor (Tac) positive lymphocytes was
elevated 5- to 30-fold and NK activity increased and LAK
activity induced in 12/16 and 8/16 patients respectively.
However, LAK inducibility in vivo did not correlate with
clinical response. Provisionally the results suggest that in situ
events are not necessarily reflected in the periphery, or that
IL-2 acts upon other components of the host response.
DNA ploidy and prognosis in superficial bladder cancer
J.R.W. Masters1, R.S. Camplejohn2, M.C. Parkinson'
& C.R.J. Woodhousel
lInstitute of Urology, University College London; 2Richard
Dimbleby Department of Cancer Research, St Thomas's
Hospital, UK.
The majority of superficial bladder cancers recur, and 10-
20% progress to muscle invasion. The course of the disease
usually is prolonged, but regular (3-12 month interval)
cystoscopic review is required, and a reliable predictor of
either recurrent superficial or muscle-invasive disease would
improve patient management. DNA ploidy was measured by
flow cytometry using nuclei extracted from paraffin sections
in an unselected series of 136 biopsies from 100 patients
presenting in 1978-1979 with a histopathological staging of
P1 disease. DNA ploidy was measurable in 107 (79%) of the
biopsies, of which 22 (21%) were diploid, 19 (18%) were
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tended to be histopathologically better-differentiated
(P<0.01) and have fewer S-phase nuclei (P<0.001). Muscle-
invasive disease was more likely to develop in patients whose
tumours had been recurrent, poorly-differentiated or aneup-
loid. None of the 16 well-differentiated tumours developed
muscle-invasive disease during a 5 year follow-up period, but
in every category a minimum of 60% of the cases recurred,
at least with superficial disease. Of the 67 cases that were
evaluable and had a complete 5 year follow-up, 61% had
developed at least one superficial recurrence, 32% had
developed more advanced disease (minimum P2) and only
7% had been completely free of disease. The results indicate
that DNA ploidy is strongly associated with prognosis, but
of less value than histopathological grade in planning patient
management, and not useful for distinguishing the prognosis
of moderately-differentiated tumours. It is concluded that
the routine measurement of DNA ploidy is of limited
assistance in this disease.
Fatty acid saturation index in peripheral blood cell
membranes of AIDS patients
N.A. Habib', K. Apostolov2, W. Barker2, S.B. Kelly',
D. Jeffries3, S.M. Forster3, R.C.N. Williamson'
& C.B. Wood4
(b) pts relapsing from first line cis-platinum therapy and
treated with phase II agents 3-20 months after cessation of
first line therapy (n=40); (c) pts relapsing 20+ months after
primary treatment (n= 17); and (d) pts receiving phase II
agents as third line or greater treatment (n= 14).
Response rates for the groups were: (a) 1/22 (4.5%); (b)
14/40 (38%); (c) 16/17 (94%); and (d) 4/14 (29%). There was
no relationship between the dose of first line cis-platinum
and response to phase II agents. No other factors appeared
to be of relevance in predicting for response on univariate
analysis, although pts in group (c) were more likely to be
entered into phase II studies once activity had been seen for
the agents in other pts. Two responding pts in group (d) had
had responses to previous treatments, but the other two
responders to phase IL agents had been non-responsive to
earlier treatments.
These data suggest that pts progressing on first line
treatment are unlikely to respond to phase II agents even if
activity is seen in vitro and in other pt groups. Patients
receiving phase II agents as third line or greater treatment
are also unlikely to respond. These observations should be
borne in mind when writing inclusion criteria for protocols
of phase II agents, to ensure that active compounds are not
missed in a disease where new treatment approaches are
required.
'Bristol Royal Infirmary; 2'4Royal Postgraduate Medical
School, London; and 3St Mary's Medical School, London,
UK.
Optimal membrane fluidity is an important factor in cell
physiology and is dependent mainly on the degree of fatty
acid desaturation of the lipids in the membrane bilayer.
Significant changes have been reported in the saturation of
fatty acids, predominantly in the ratio of stearic to oleic
acid, in erythrocyte cell membranes of cancer patients (Wood
et al., Br. Med. J., 291, 163, 1985). This ratio is referred to
as the saturation index (SI).
In this study, the lipid analysis of peripheral blood cells
from patients with AIDS (n= 12) and control subjects
(n=24) was investigated by gas liquid chromatography.
The SI was significantly lower (P<0.0001) in AIDS
patients (means: RBC=0.18; WBC=0.11) compared to the
controls (means: RBC= 1.03; WBC= 1.40). This suggests the
HIV could be responsible for the low SI seen in peripheral
blood cells of AIDS patients. It is also interesting that the
index is differentially lower in the WBCs, the target cells of
the AIDS virus.
This desaturation of peripheral cell membranes could
partly explain the systemic metabolic disturbances seen in
this infection.
Some patients with epithelial ovarian cancer (EOC) relapsing
from first line therapy will never respond: Prediction of these
patients and implications for phase III studies
F. Lawton, C. Redman & G. Blackledge
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Hospital, Birmingham B15 2TH, UK.
Median survival for patients (pts) with EOC from first
relapse or progression is 5-6 months. New drugs are needed
in EOC but must be tested in pts who are appropriate to
demonstrate activity. Between May 1983 and June 1987, 93
pts with EOC were entered into 4 phase II studies of
chemotherapy. The regimens had been chosen on the basis
of in vitro cytotoxicity data. 35/93 (38%) responses were
seen. In an attempt to identify which pts might be most
likely to respond, pts were divided into the following groups:
(a) pts progressing on first line cis-platinum therapy (n=22);
Comparison of toxicity of mitozantrone and doxorubicin
when used in combination with vincristine and prednisolone
for advanced breast cancer
V.L. Hall, R.B. Buchanan & C.J. Williams
Combined Breast Clinic, Royal South Hants Hospital,
Southampton S094PE, UK.
Mitozantrone (M) is less toxic than doxorubicin (D) in
controlled single agent trials though there is little compara-
tive data when they are used in combination. In this trial
patients with advanced breast cancer were randomly assigned
to vincristine (V) 1.4mgm-2 (max. 2.0) i.v. DI and 8, D
40mgm-2 i.v. Dl and 8, prednisolone (P) 12mgm-2 PO
DI-14 q28 days (VAP) or the same doses of V and P
together with M 14mgm-2 i.v. Dl and 8 (VMP). Sixty
patients were randomized (30 to each arm). They were well
balanced for prognostic factors (age, menopausal status,
disease free interval, sites of disease). Overall response rates
were VMP 48% and VAP 44%. Median response duration
was VMP 9.6 mo, VAP 5.9 mo (log rank P=0.2). Median
survival was VMP 14.6 mo VAP 10.5 mo (log rank P=0.5).
There were no significant differences (Mann-Whitney U test)
for the following toxicities: nausea, stomatitis, performance
status, neuromuscular. All patients were offered head cooling
and most started this (VAP 25, VMP 24). Alopecia was
significantly more severe for VAP (third cycle P=0.0002,
sixth cycle P=0.02), though most VMP patients had WHO 2
toxicity by the sixth cycle. By the third cycle anaemia and
neutropenia were significantly more severe in VMP
(P=0.01). One VAP patient died of heart failure, in
remission, 6 mo after chemotherapy. One other had WHO
grade 2 toxicity. One VMP patient died of sepsis during
chemotherapy. Quality of life assessment revealed no signifi-
cant differences between VMP and VAP. Using this combi-
nation the only significant reduction in subjective toxicity for
M was a marginal reduction in alopecia. This is at the
expense of significantly greater neutropenia and anaemia.
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Mitozantrone or doxorubicin with vincristine and
cyclophosphamide (VNC vs. VAC) in the treatment of
advanced breast cancer
A.J. Slater' & J.A. Green2 for the Mersey Breast Group
'Mersey Regional Centre for Radiotherapy and Oncology
and CRC Department of Radiation Oncology, Clatterbridge
Hospital, Merseyside L634JY, UK.
This randomised study asks the question whether mito-
zantrone in combination can achieve equivalent disease
control with reduced toxicity compared to doxorubicin.
Seventy-one patients (13 pre-, 57 post-menopausal and 1
male) with a mean age 54.5 (range 28-77) have been
randomised to receive either vincrinstine 1.4 mgm-2 i.V.,
mitozantrone 10 mgm-2 i.v., cyclophosphamide 600mgm -2
i.v. (VNC), or vincristine 1.4mgm-2 i.v., doxorubicin
50 mgm-2 i.v., cyclophosphamide 600mgm-2 i.v. (VAC),
both given with a cycle time of 21 days. The coded results
are as follows: on arm A out of 36 patients there have been
10 CR, 12 PR, 5 SD, I PD and 8 NE with the median time
to relapse in the responders of 33 weeks. On arm B out of 35
patients there have been 3 CR, 13 PR, 12 SD and 7 PD and
the median duration of response was 24 weeks. The mean
number of cycles given on arm A was 4.4 and arm B 4.1.
WHO grade 3/4 alopecia was observed in 23 patients on
arm A and 10 patients on arm B. Nausea and vomiting
grade 3/4 was seen in 13 patients on arm A and 11 patients
on arm B. Myelosuppression was similar in both arms. No
patient has discontinued chemotherapy on account of bone
marrow toxicity, but one patient experienced profound
hypocalcaemia in VNC and treatment was stopped. There
have been no toxic deaths. The present study has shown
important differences in response rate, duration of remission
and toxicity between VAC and VNC in the preliminary
analysis, and remains open to entry.
Chemotherapy in poor risk germ cell tumours: An
independent evaluation of POMB/ACE (cis-platinum,
vincristine, methotrexate, bleomycin/actinomycin-D,
cyclophosphamide, etoposide)
N.S. Stuart', M.H. Cullen', P. Harper2, C.M. Woodroffe',
P. Kirkbride2 & J. Clarke2
'Queen Elizabeth Hospital, Birmingham; and 2Guy's
Hospital, London, UK.
The seven drug, alternating, high-dose cis-platin regime,
POMB/ACE, has been reported by the Charing Cross Group
(CCG) as producing excellent results in all patients with
advanced germ cell tumours. We have independently eva-
luated this regime in 60 poor risk patients; 55 patients with
advanced teratoma and 5 with bulky, relapsed seminoma.
Five teratoma patients had relapsed following previous
chemotherapy (CT) or radiotherapy (XRT) or both, 13 had
extragonadal tumours, 6 had hepatic and 4 cerebral meta-
stases. Twenty-eight patients had 'high markers' by MRC
criteria and 22 'very high markers' by CCG criteria. The
primary testicular patients comprised 16 with 'large volume'
and 21 with 'very large volume' disease by MRC criteria.
The CT regime used was that reported by Newlands et al.
(1983,1986) with the difference that CT was continued for
only two courses (one full cycle) beyond marker remission
with a minimum of 5 courses. Intrathecal methotrexate was
given to only one of the patients with cerebral metastases
(mets) and none received XRT. Tumour masses remaining
after CT were resected if possible.
The median number of courses of CT received by patients
completing treatment was 6 (range 5-13). Median follow-up
is 32 months. Overall 2-year actuarial survival (AS) is 74%
with all 14 deaths occurring within 16 months of start of
treatment. For the 'very high marker' group, 2-year AS is
60%; for the low marker group, 84%. These figures are very
similar to equivalent groups in the CCG series. Using MRC
prognostic criteria patients with 'large volume' and 'very
large volume' disease had similar survival while the 'high
marker' group had a significantly worse 2-year AS than the
'low marker' group (58% vs, 91%, P<0.01). Four of the 6
patients with hepatic mets and 3 of the 4 with cerebral mets
are alive in remission. Sixty patients were evaluable for
toxicity. Septicaemia occurred in 5 patients, auditory loss in
10, severe neuropathy in 2, persistent CT induced vomiting
requiring re-admission in 5 and impaired renal function in 8.
There were three treatment related deaths.
We conclude that POMB/ACE is an effective regime in
the treatment of poor risk germ cell tumours even when a
shorter treatment duration that originally described is used.
We confirm the prognostic significance of high tumour
markers. We feel the complexity and toxicity of this regime
makes it inappropriate for the treatment of good risk
patients.
Intensive platinum based combination chemotherapy
(BOP/VIP) for germ cell tumours with the worst prognosis
M. Harding', C. Bradley', C. Lewis', L. Mill',
J.J. Keizer', M. Soukopl & S. Kaye'
'Department of Medical Oncology, University of Glasgow,
UK; 2University of Leiden, The Netherlands; and 3Glasgow
Royal Infirmary, UK.
Glasgow data show that patients with very high volume
metastases (MRC definition) from testicular germ cell
tumours or extragonal primary sites, have 2 year survival
rates of 58% and 25% respectively. This pilot study was
designed to improve these results. To date 27 patients
(median age 33 years) have completed therapy with nodal
disease > 1O cm (n=7), advanced pulmonary metastases
(number >20 and/or >3 cm: n=4), brain (n=1), bone
(n = 1) or liver (n=4) involvement or extragonadal primary
sites (n = 10: all with lesions >7 cm). Twenty-three of 24
patients with teratoma were marker producing: median HCG
level 93,750u1 ' (561-1.6x 106), median AFP6, 170uml
(125-73, 800).
Treatment comprised 3 cycles of CDDP 50mgm 2 days 1
and 2 with vincristine 2mg and bleomycin 30mg day 1 at 7-
10 day intervals (BOP): then 3 courses of CDDP 20mgm 2,
ifosfamide 1.2mgm-2 days 1-5 with VP16 75-100mgm-2
days 1, 3, 5 (VIP) q 3 weekly. Grade 4 myelotoxicity
necessitated reduction in VP16 dosage in 7 of 10 patients
receiving 100mgm-2: 2 septicaemias occurred. Toxicity
requiring protocol modification was neuropathy (n=2) and
renal failure (n=1); 3 patients developed significant neuro-
pathy after completion of BOP/VIP.
Twenty-six patients are evaluable for response: 12 achieved
surgically confirmed complete remission (CR) and immature
teratoma was resected from a further 4. Three patients
reached clinical CR and 6 a partial remission (PR) only; of
these 2 continue on treatment but 4 have relapsed. A single
patient had a marker PR but no radiological response.
Eighteen patients are disease free with a median follow-up of
12 months (6-24). A further 16 patients are currently on
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Intensive weekly combination chemotherapy for initial
treatment of advanced intermediate and high-grade non-
Hodgkin's lymphoma (NHL)
J.W. Sweetenham, J.M.A. Whitehouse & G.M. Mead
CRC Wessex Medical Oncology Unit, Southampton General
Hospital, Southampton, Hants. S094XY, UK.
High response and survival rates have been reported for the
MACOP-B regimen in aggressive NHL (Ann. Int. Med., 102,
506, 1985). The major toxicity of this regimen was mucositis
related to methotrexate (MTX). We have devised a similar
regimen for a comparable group of patients with a reduced
dose of MTX, but with the addition of etoposide.
From June 1986 to November 1987 30 patients (pts),
median age 58 (33-69), with NHL (intermediate and high
grade) entered a prospective trial of intensive weekly chemo-
therapy comprising: A - Adriamycin 35mgm 2 i.v. dl,
cyclophosphamide 300mgm-2 i.v. dl, etoposide 150 mgm-2
i.v. dl. B - MTX 100mgm-2 i.v. d8 (with LV rescue),
bleomycin 0mgm-2 i.v. d8, vincristine 1.4mgm-2 i.v., d8.
A and B given in a 2-weekly cycle for 6 cycles of each.
Prednisolone 50mg daily given weeks 1-4 then on alternate
days weeks 5-12. Prophylactic co-trimoxazole given through-
out. Dose modifications exactly as for MACOP-B. Intrathe-
cal MTX and cytosine arabinoside were given to
marrow+pts.
Patient characteristics: Number currently evaluable - 20.
Histology (WF): DLC (14), DM (4), Immunoblastic (2);
Stage: II (>10cm) (2), III (9), IV (9) (Marrow +5). B
symptoms (8). Outcome: 12/20 CR (2) subsequent relapses (1
death). 3/20 PR but with resolving radiological abnormal-
ities. 2/20 PR with subsequent progression (1 death).
One neutropenic death. One death from gastric perfor-
ation on treatment. I death from WI on treatment.
The dose limiting toxicity has been mucositis. Myelo-
suppression has not been severe. This intensive regimen has
proved to be effective in tis preliminary study, with manage-
able toxicity. Updated results will be present.
Spinal cord compression in small cell lung cancer
R.L. Souhamil, C.M. Ash' & J.M. Goldman2
'Department of Oncology, University College London and
Middlesex School of Medicine, London; 2Brompton
Hospital, London, UK.
The records of 610 consecutive patients taking part in a
randomised trial in small cell lung cancer were reviewed and
24 (4%) cases of spinal cord compression (CC) identified.
Five hundred patients had isotope bone scans performed,
and in 131 (26%) there was abnormal isotope uptake in the
spinal column, only 7% of these patients developed CC.
However, of the 25 patients who presented with back pain
and had a positive bone scan affecting the spine, 36%
developed CC. The incidence of cerebral metastases in the
trial was 19.5% and in patients with CC 45%. The combi-
nation of cerebral metastases and a positive bone scan gave
a 25% chance of developing CC. There were 2 distinct forms
of clinical presentation. Six patients (Group A) presented
with CC, all had back p4in and positive bone scans, 5 out of
6 had sphincter disturbance. Median survival from CC was
30 weeks. Eighteen patients (Group B) developed CC whilst
on treatment, 28% had positive bone scans, 44% back pain
and 61% sphincter disturbance, median survival from CC
was 4 weeks. Overall median survival was 30 weeks in
Group A, 34 weeks in Group B and 37 weeks in the
multicentre trial. Three patients received surgical treatment
(survival 17, 55 and 57 weeks). Fourteen patients received
radiotherapy, median survival 6 weeks, and 7 patients
received symptomatic treatment, median survival 4 weeks.
CC is an important cause of morbidity and mortality in
small cell lung cancer. The study shows that it is possible to
select patients at high risk (those with back pain and positive
bone scans, and those with cerebral metastases and positive
bone scans) who should receive radiotherapy as prophylaxis
against this complication.
Mathematical modelling in locally advanced breast cancer
(LABC)
M.A. Richards, W.M. Gregory & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London on
behalf of the EORTC Breast Cancer Cooperative Group,
UK.
A mathematical model has been developed to study mecha-
nisms of tumour response and applied to data from a study
of LABC. Patients were randomly allocated to treatment
with radiotherapy (RT), RT+chemotherapy (CT), RT+en-
docrine therapy (ET) or RT+CT+ET. The best fit curves
derived by the model give the mean +s.d. of the number of
residual tumour cells and the- mean and spread of tumour
doubling time (DT).
The model fitted the actuarial curves for time to local
progression well for RT and RT+CT. It was estimated that
the addition of CT reduced the mean number of local
tumour cells by an extra 2 logs. The DTs for RT and
RT+CT were similar (means 21.4 and 23.5 days). The model
gave only a poor fit for the actuarial curve for patients
treated with RT+ET. Further application of the model to
separate intervals on this curve suggests that ET resulted in a
cell kill similar to that of CT and also caused growth arrest
in a proportion of patients for a mean of 14 months.
Growth thereafter was similar to that for patients treated
with RT only. For time to distant metastases, neither CT
nor ET reduced the micrometastatic tumour burden signifi-
cantly, when compared with that estimated for patients
receiving RT only. The model estimates for the doubling
times of locally recurrent tumours and distant metastases
following RT alone or RT+CT were similar.
The results suggest either a difference in chemosensitivity
between primary and metastatic cells or that RT enhances
response to CT. The model will be of value in the design of
new clinical trials.
Combination chemotherapy for adenocarcinoma of unknown
origin
T.S. Ganesan, P. Clark, R.J. Osborne, S. Malik,
M.L. Slevin, P.F.M. Wrigley & R.I.D. Oliver
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, Smithfield, London ECIA 7BE, UK.
Poorly differentiated adenocarcinoma or undifferentiated
carcinoma, is a common problem in clinical practice. Treat-
ment of this clinical syndrome with teratoma-like chemo-
therapy may result in long-term remission for a proportion
of younger patients (Greco et al., Ann. Int. Med., 104, 547,
1986), though careful selection of patients with particular
disease patterns may be required. From 1983 to 1987, 15
patients (10 females and 5 males), with metastatic adeno-
carcinoma of unknown primary origin was treated with BEP,
bleomycin 30mgday-1 i.v. infusion days 1-3, cis-platinum
40 mgm 2 i.v. days 1-3, etoposide 120mgm-2 i.v. days 1-3,
repeated every 21 days, at least 3-4 courses were given to
each patient.
The median age of the patients was 38 years with a range
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in patients were lung 12, liver 6, bones 7, brain 2, lymph-
nodes 5, skin 1 and fundus 2. Two of 15 patients had disease
confined to the lung, one confined to the bone, and one to
the pelvis. Alpha-foetoprotein and HCG levels were normal
in all patients. Fourteen of 15 patients had poorly differen-
tiated or undifferentiated adenocarcinoma and one patient
had a well differentiated tumour. Five of 15 patients (2 CR,
3 PR) responded to therapy, 6 of 15 patients were unrespon-
sive, and there were 4 of 15 early deaths (after one cycle of
treatment). One patient with CR relapsed 2 months after
completion of therapy, and the other patient having had
previous radiation to the chest died in CR due to bleomycin
toxicity. Two of 15 patients are alive (1 PR, 1 fail) at the
time of the report. Lung toxicity was observed in 6 of 15
patients (assessed by PFT and chest X-ray) and in 1 patient
it was fatal. Renal toxicity was observed in 4 of 15 patients
and in 2 of 15 it was fatal. Post mortem examination was
performed in 6 of 15 patients: 3 patients had a primary
tumour in the lung, I patient died of severe bleomycin
toxicity (having had previous chest irradiation) without any
residual tumour detected, and in 2 patients a primary site
could not be located. This regime was considerably more
toxic in this group of patients than in the younger patients
with teratoma receiving the same regimen, and there were no
long-term survivors.
A randomised double-blind cross-over trial of dexamethasone
and lorazepam with or without high dose metoclopramide
infusion in the treatment of chemotherapy induced emesis
M.E.R. O'Brien1, M.H. Cullen1, C. Woodroffe1,
K. Kelly1, C. Burman', K. Palmer2, G.R.P. Blackledge2
& J. Sharpe2
1Cancer Research Campaign, Clinical Trials Unit, Queen
Elizabeth Hospital and 2St Chad's Hospital, Birmingham,
UK.
High dose metoclopramide (MET) is an effective anti-emetic
for use with cis-platin containing chemotherapy regimens but
can cause extrapyramidal reactions (EPR). Lorazepam (L)
and dexamethasone (D) are being used increasingly to
alleviate chemotherapy induced emesis. This trial addresses
the question 'does high dose MET contribute to anti-emetic
control when given with dexamethasone and lorazepam?
Eighty-one patients have entered a randomised double blind
cross over trial comparing lorazepam and dexamethasone
with or without high dose MET. Lorazepam 2mgm-2 was
given with dexamethasone 8 mg i.v. and either MET
1 mgkg-I or a placebo of N Saline 60min before chemo-
therapy. This was followed by a 24 h infusion of MET
9 mg kg 1 or placebo with 4 mg boluses of dexamethsone 4
hourly i.v. If there is no vomiting patients then receive oral
dexamethasone 4 mgqds plus either MET 20 mgqds or
placebo tablets for 3 days. Patients were crossed over for the
second course of treatment and then chose their preferred
regimen for subsequent treatments. Randomisation was stra-
tified according to whether or not the patient will be
receiving cis-platin. Fifty-four patients are assessable having
completed two courses and stated a preference, 29 received
LD Met first and 25 LD Plac first. The chemotherapy
regimens were given for a range of gynaecological and other
malignancies, 48 contained cis-platin and 6 non-cis-platin
regimens. The mean number of episodes of vomiting during
the first 24h for first and second courses (see Table) was
significantly fewer when receiving LD Met than with LD
Plac (P<0.0001).
The difference in nausea control also significantly favoured
the 3 drug regimen (P<0.0004). However, there was no
difference in the control of nausea and vomiting during the
following 3 weeks. Nausea was significantly more prevalent
during the period after the 2nd course of chemotherapy
compared with the 1st, irrespective of anti-emetic regimen
(P<0.007). Vomiting was completely abolished in 45% of
patients, and 69% had major control (.2 episodes) when
they received LD Met on first exposure to chemotherapy.
More patients stated a preference for the 3 drug regimen
although this is not statistically significant. EPR were
recorded in 14% of patients receiving MET. In conclusion
the combination of dexamethasone and lorazepam can give
major control of emesis in 25% of patients but with the
addition of metoclopramide the control of both nausea and
vomiting are significantly improved.
BRL43694, a selective 5-HT3 receptor antagonist: Dose
ranging study for control of cis-platin induced emesis
J. Carmichael1, B. Cantwell', G. Rapeport1, P. Coates',
S. Thompson1 & A.L. Harris1
1University Department of Clinical Oncology, Newcastle
upon Tyne; and 2Beecham Pharmaceuticals Research
Division, Harlow, Essex, UK.
Thirty-eight patients receiving cis-platin (CP), either alone or
in combination, were treated with BRL43694 (BRL), a new
selective 5-HT3 receptor antagonist. BRL was administered
as a 30min infusion immediately following a 30 min CP
infusion. The starting BRL dose was 10 pgkg-1, with 8
patients receiving up to 30 pgkg- 1 with clinical benefit
observed above 20 pgkg-1. Of 14 pts treated at 40pgkg-1
BRL, complete control of CP induced nausea and vomiting
was achieved in 8 (57%), over 24 h, with the onset and
severity of these symptoms significantly modified in the
remaining 6 patients. Symptoms of nausea were assessed
using linear visual analogue scores (VAS) and global rating
scores. No unexpected toxicities were observed, as deter-
mined by a systematic enquiry covering 35 general questions,
and in particular, symptoms of anxiety or sedation were not
problematical. 24h Holter monitoring revealed no significant
arrhythmias. Detailed pharmacokinetic studies were per-
formed at BRL doses of 40 pgkg-1 and these showed wide
inter-individual variation: Mean values (range) for Cmax
33ngml-1 (11-81); Cl 0.235 (0.035-0.602)lh-1kg-1; VD
2.291kg - (1.06-4.2); AUC 353 ngkml1 (66-1127) and t41/2
10.4h (2.9-21).
One patient with SVC obstruction developed transient
renal impairment following CP, and in this patient BRL
levels remained elevated over 24h, suggesting that the drug
is predominantly excreted by the kidney. BRL is an effective,
safe and well tolerated anti-emetic for the control of CP
induced nausea and vomiting. Further studies have been
performed at BRL doses of 80 ,gkg-' (3 pts) and
120 pgkg-1. Sixteen patients have received the latter dose
either as a single 30 min infusion or by a split dose schedule.
Both of these schedules have been effective with no acute
side effects.
Balancing the possible benefits against the risk of cytotoxic
chemotherapy - Patients' and doctors' decisions
M.L. Slevin, H. Plant, L. Stubbs, P. Wilson
& K. O'Sullivan
ICRF Department of Medical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
Estimates of patients' willingness to tolerate adverse side
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effects of cytotoxic chemotherapy are largely a matter of
clinical intuition. A study has been conducted to investigate
how patients balance the benefit and cost of chemotherapy
and to compare this to the response of cancer specialists to
the same questionnaire. One hundred and six patients and
165 cancer doctors (60 medical oncologists, 87 radiothera-
pists, 18 others), completed questionnaires which invited
responses to two fictional cytotoxic treatments (intensive
treatment and mild treatment). All subjects were asked to
assess their willingness to undergo these two treatments in
three hypothetical situations: (1) chance of cure; (2) prolon-
gation of life; (3) relief of symptoms. There were significant
differences between patients and doctors responses in each of
the three parameters in both treatment situations. Offered
intensive treatment 53% of patients were willing to accept
1% chance of cure whereas 11% of doctors would do so
(P=0.001). In the prolongation of life question 42.1% of
patients would accept treatment which might extend their
lives by 3 months; 3.7% of doctors would do the same while
75% of doctors would require an extension of at least a
year. Offered treatments with expected mild toxicity, both
patients and doctors were prepared to accept a lower chance
of success. Sixty-seven percent of patients and 39% of
doctors would accept a 1% chance of cure. Prolongation of
life for the minimum 3 months was acceptable to 53.8% of
patients and 27% of doctors (P<0.0001). These data suggest
that most patients are prepared to undergo intensive therapy
for very little chance of benefit and may be unable to make
rational decisions about treatment on their own.
Posters
A randomised double blind placebo controlled trial of
medroxyprogesterone acetate (MPA) in cancer cachexia
D.C. Talbot, M.L. Slevin, S.P. Joel, L. Stubbs, H. Plant,
A. Allbright, D. Lynch & B. Hemmings
ICRF Department of Medical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
Patients with breast cancer treated with MPA often report
an increased appetite. MPA has a potential advantage over
corticosteroids in that it does not exert a catabolic effect.
MPA (100mg tds orally) has therefore been compared with
placebo in 60 patients with advanced malignant diseae (33
Ca lung (26 oat-cell, 7 non-oat-cell), 5 mesotheliomas, 3 Ca
colon, 3 NHL, 3 Ca ovary, 2 Ca breast, 2 myelomas, 9
other). Twenty-one patients in the MPA group and 20 in the
placebo group were receiving chemotherapy. Patients were
treated for 6 weeks and were assessed at weeks 0, 3 and 6
for appetite, mood and energy using linear analogue scales
and serum proteins as indicators of nutritional status. There
was a significant improvement in appetite in the MPA group
between assessment 1 and 2 (P=0.0002) and 1 and 3
(P=0.015). There was significant improvement in appetite in
the placebo group. This improvement in appetite in the
MPA occurred in both patients with oat-cell lung cancer and
those with other malignancies. Supporting this finding was
the significant increase in serum thyroid binding pre-albumin
and retinol binding protein in the MPA group between
assessment 1 and 3 (P=0.023 and P=0.039 respectively).
These two parameters showed no significant change in the
placebo group. There was no change in performance status,
energy, mood or pain in either group. This data indicates
that there is an apparent increase in appetite in anorexic
patients with advanced cancer treated with MPA which is
reflected in increases in protein indicators of nutritional
status. However, this apparent increase in appetite did not
result in improved weight, performance status or mood.
expression were also correlated to lymph node status and
tumour grade. In 29 of 95 (30%) tumours intensive mem-
brane staining indicative of C-erbb2 was noted using the
monoclonal antibody to the 21 N peptide (C terminus
residues 1243-1255). In positive specimens heterogeneity of
expression was noted throughout. Of the 29 positive tumours
axillary lymph node metastases were present in 25 of the
cases (86%). Among these 29 cases the average age was 50
years (range 36-79). No correlation was noted between C-
erbb2 expression, ER status and tumour grade (Table).
Among the 66/95 (70%) of C-erbb2 negative tumours lymph
node metastases were detected in only 27% and the average
age was 56 years (range 32-85).
C-erbb2 Mean % Grade
expression Number age % ER+ III %LN+
Positive 29 50 50 65 86a
Negative 66 56 65 46 27
ap< 0.001.
These data suggest a strong correlation between C-erbb2
amplification in breast cancer and axillary lymph node
metastases. Thus the presence or absence of C-erbb2 gene
amplification may be a significant predictor of disease
progress and long term survival in patients with breast
cancer.
Mitozantrone and ifosfamide in metastatic breast cancer
D. Parker. M.K. Gough, A.K. Hancock, M.B. Masood,
B. Gadsby-Peet & J.J. Price
Oncology Unit, Bradford Royal Infirmary, Bradford
BD96RY, UK.
Inmunohistochemical analysis of C-erbb2/her-2/neu in breast
tumours
P. Johnston', P. Dervan', A. McCann', L. Doyle',
B. Guillick2 & D.N. Carney'
'Mater Misericordiae Hospital, Dublin, Ireland; and
2Imperial Institute of Cancer Research, London, UK.
Using an immunohistochemical technique we have evaluated
and compared the expression of C-erbb2 oncogene and ER
status in 95 primary breast tumours. Results of C-erbb2
The combination of an anthracycline and alkylating agent
has been shown to be synergistic in both animal models and
clinical breast cancer. We have used the combination of
mitozantrone (10mgm-2 i.v.) with ifosfamide and MESNA
1 gm-2 i.v. days 1-3 as an infusion. The treatment was
repeated every 3 weeks. The dose of both drugs was designed
to increase the therapeutic index of the combination and in
particular to reduce both nausea and alopecia.
Twenty patients have beentreated with this combination,
four of whom were pre-menopausal. Thirteen patients had
local disease, 9 had pleural or pulmonary disease and 9 had
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response to the combination and 2 patients had static
disease. Toxic effects included moderate neutropenia without
clinical infection and frequent nausea/vomiting. Noticeable
alopecia affected the majority of patients.
This combination shows moderate activity in metastatic
breast cancer, but the regimen has not substantially reduced
the nausea and alopecia associated with alkylator/
anthracycline combinations.
A phase II study of mitozantrone in advanced breast cancer
P.I. Thompson & V.J. Harvey
Department of Clinical Oncology, Auckland Hospital,
Auckland, New Zealand
Mitozantrone is a synthetic anthracenedione which has been
reported to produce a similar response rate to doxorubicin in
advanced breast cancer with a relative absence of acute side
effects. Fifty-six patients with advanced breast cancer have
been treated. Mean age was 53 years (range 35-75 years) and
average Karnofsky score at commencement of therapy 72%.
Initial dosage was 12mgm 2 with provision for escalation.
Fifty-three patients are evaluable for response, all having
completed therapy. Eleven patients (21%) achieved a partial
remission with remission durations of 4-16+ months. Ten
patients (19%) had static disease and maintained this for 3-
19+ months Thirty-one patients (58%) had progressive dis-
ease. The response rate in previously treated patients was
13% (5/38) but increased to 40% in the 15 previously
untreated patients. Improvement in quality of life as mea-
sured by a symptom score, linear analogue scale assessment
(LASA) score, category score and Karnofsky performance
status correlated with objective response. Therapy was well
tolerated by patients. Haematological toxicity was significant
with dose modification frequent, resulting in a mean dose
achieved per 3 week cycle of 9.1 mgm-2 both overall and in
responding patients. Gastrointestinal toxicity was mild.
Seventeen patients (30%) experienced some hair loss but in
all this was only mild. There was no clinical or ECG
evidence of cardiotoxicity. Mitozantrone offers a useful
alternative to combination chemotherapy as first line treat-
ment in less fit patients but its role in previously treated
patients is less well defined.
Aminoglutethimide and estramustine: Combined endocrine
therapy in advanced breast cancer
D. Parker, M.K. Gough, A.K. Hancock, M.B. Masood,
B. Gadsby-Peet & J.J. Price
Oncology Unit, Bradford Royal Infirmary, Bradford
BD96RJ, UK.
Twenty-six post-menopausal patients with metastatic breast
cancer were treated with escalating doses up to a maximum
of 1 G aminoglutethimide and 520mg estramustine daily.
Aminoglutethimide was given with estramustine as it was
thought that estramustine might occupy oestrogen receptor
sites vacated by the action of aminoglutethimide in reducing
free oestrogen. The mean age of the patients was 55 years,
mean 11 years post-menopausal. Nineteen patients had bone
metastases demonstrated by scintiscan and 8 patients had
liver metastases shown by computerised tomographic scan.
Sixteen patients had local disease. Twenty had received
adjuvant cytotoxic therapy and 23 had received previous
endocrine therapy. There were two objective responses, one
complete clinical response of local disease and one partial
response in lung, bone and liver metastases. Eleven patients
had nausea and vomiting which led to 3 patients stopping
treatment.
This low response rate suggests that aminoglutethimide
and estramustine are antagonistic. This may be due to
induction of liver enzymes by the aminoglutethimide leading
to enhanced hydrolysis of estramustine with release of free
estradiol or estrone. The combination of aminoglutethimide
and estramustine cannot be recommended for the treatment
of advanced breast cancer.
Weekly epirubicin for lver metastases in breast cancer
C.J. Twelves, R.E. Coleman, S. O'Reilly, M.A. Richards
& R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
Patients with breast cancer who develop liver metastases
have a poor prognosis. Administration of chemotherapy is
difficult; in particular, anthracyclines may cause severe toxi-
city because of reduced hepatic drug clearance. We have
studied the efficacy and toxicity of epirubicin using a weekly
schedule, adjusting dose intensity according to
myelosuppression.
Between November 1986 and February 1988 we treated 28
consecutive patients with liver metastases demonstrated by
isotope or ultrasound scan, who had an AST>2 x normal or
bilirubin >20pmol1-1. Median age was 56 years (range 27-
78) and median UICC performance status was 2 (range 1-3).
None had received prior anthracyclines, but 6 had received
other chemotherapy (2 as adjuvant treatment). Epirubicin
25mgm2 i.v. was given weekly. Dosage adjustments were
not made for abnormal liver biochemistry, but if the
WBC<2.0x1091 1 or platelets <70x1091-1, treatment
was delayed until these levels were reached.
It is too early to assess response in 2 patients. Of the 26
patients assessable to date, 1 had a complete remission and 8
a partial remission (UICC); 3 others had a >50% improve-
ment in liver biochemistry. All responders improved sympto-
matically. During the first month of treatment, 6 of the 12
responding patients had a >25% deterioration in AST or
bilirubin, but liver biochemistry subsequently improved as
chemotherapy continued. All patients are evaluable for toxi-
city; 4 had WHO grade III or IV vomiting, 1 grade III
stomatitis and 6 grade III myelosuppression.
In patients with advanced liver metastases from breast
cancer, weekly epirubicin is well tolerated and has a >30%
response rate. An initial deterioration in liver biochemistry
may occur before there is a response.
APD treatment of bone metastases from breast cancer
R.E. Coleman, P. Woll & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London
SE] 9RT, UK.
Osteoclastic bone destruction is inhibited by the biphospho-
nates and repeated administration may achieve long-term
control of oesteolysis. In this study we have investigated the
effect of APD (3 amino-1, 1-hydroxypropylidene bisphos-
phonate) on bone metastases from breast cancer.
Twenty-eight patients with progressive symptomatic bone
metastases received APD 30mg as a 2 h intravenous infusion
every 14 days. No other systemic therapy for breast cancer
was prescribed and APD continued until the development of
progressive disease. Patients were assessed for objective
response by the UICC criteria. In addition, subjective res-
ponse was determined by a pain questionnaire and bone
metabolism monitored by serial biochemical measurements.
Response in bone assessable in 24 patients. Evidence of
bone healing with sclerosis of lytic metastases (PR) occurred
in 4 patients. The median duration of response was 10+
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(median 5 months), and 10 progressed. Symptomatic res-
ponse occurred in 10 patients. Biochemical monitoring indi-
cated selective inhibition of osteolysis with no effect on
oestoblast function. Treatment was tolerated well without
toxicity.
APD is a potent inhibitor of osteolysis and a valuable new
treatment for the palliation of bone metastases. The role of
APD in conjunction with established systemic therapy is to
be studied in a randomised phase III study.
Single high dose (45mg) infusions of
aminohydroxypropylidene diphosphonte (APD) for severe
malignant hypercalcaemia
B.M.J. Cantwell, J. Carmichael, K.A. Mannix
& A.L. Harris
University Department of Clinical Oncology, Newcastle
General Hospital, Newcastle upon Tyne NE46BE, UK.
We previously found that single i.v. infusions of 30 mg APD
were effective in lowering serum calcium and induced
normocalcaemia in 10 (63%) of 16 patients with malignant
hypercalcaemia. Those that did not achieve normocalcaemia
tended to have the highest pretreatment serum calcium levels
(Cantwell & Harris, BMJ, 294, 467, 1987). To induce
normocalcaemia in a greater proportion and to maintain the
advantages of single infusion therapy we gave single infu-
sions of 45mg APD in 750ml normal saline, infused i.v.
over 3 h to 27 patients with malignant hypercalcaemia.
Intravenous hydration with 31 of normal saline daily was
given with APD infusions. Serum calcium levels were
adjusted for albumin. The majority had severe hyper-
calcaemia, MEAN serum calcium was 3.57 mmol 1- (normal
range 2.25-2.75 mmol 1 ') and 15 patients had levels
>3.5mmoll-1 with 2 having levels >4mmoll-1. There
were 16 males and 11 females, 8 had non-small cell lung
cancer, 7 had breast cancer and the remainder a variety of
other cancers. Sixteen were resistant to prior calcium lower-
ing therapies. After a single 45 mg infusion of APD 22
(81%) patients achieved normocalcaemia, including 2
patients with pre APD serum calcium levels >4mmoll-1.
One patient only showed no response and the mean NADIR
level after APD in 26 patients who responded was
2.57 mmol 1 '. Three patients had mild temporary hypo-
calcaemia and 1 patient whose pre-APD serum calcium was
3.20 mmoll- had prolonged hypocalcaemia after APD
(serum calcium = 1.99 mmolI1 day 26). Single infusions of
APD 45 mg are well tolerated and effective for the majority
of patients with severe malignant hypercalcaemia.
High dose etoposide at varying schedules for metastatic
bronchogenic carcinoma
W.P. Steward', P.M. Wilkinson2, J.M. Edmundson2
& N. Thatcher'
'CRC Department of Medical Oncology and 2Department of
Clinical Pharmacology, Christie Hospital and Holt Radium
Institute, Manchester M209BX, UK.
Sixty previously treated patients (pts) with metastatic small
cell and non-small cell lung cancer were treated with up to 6,
3-weekly intravenous infusions (inf) of etoposide given either
over 45 min or 24 h. Dosages used were either 600 mgm-2 or
900mgm-2.
Median follow-up was 7.5 months (range 1-32 months).
Partial responses were seen in 2 pts and disease was static
during treatment in 11 pts. Duration of response was short
(6 and 9 weeks). Median survival from starting treatment
was 3 months for all patients - no significant difference
between treatment schedules or according to histology. There
were two treatment related deaths.
Pharmacokinetic data from 26 pts (using HPLC analysis
of serial serum specimens over 48 h following drug admini-
stration) showed peak drug concentrations were 10-fold
higher with 45min infusions compared with 24h inf (mean
[Lm]-390 vs. 28.9 at 600 mgm 2 and 394 vs. 36.9 at
900mgm-2). The AUC increased proportionately and signi-
ficantly with the higher dose by either short or 24h inf
(mean+s.d. [limol.1-l]; 1,006 (±160) for 600mgm 2 inf;
842 (±218) for 600 mgm-2 24h inf; 1,419 (±262) for
900mgm-2 short inf; 1,038 (±424) for 900mgm-2 24h
inf).
The AUC was greater for the 45 min compared to the 24h
inf, for each dose but this was not significant. The higher
weak concentration and greater AUC produced by bolus
administration requires further investigation in more sensi-
tive tumours.
Disease relapse in patients with stage I non-seminomatous
germ cell tumour of the testis on active surveillance
P.I. Thompson & V.J. Harvey
Department of Clinical Oncology, Auckland Hospital,
Auckland, New Zealand.
Thirty-six patients with apparent stage I non-seminomatous
germ cell tumour (NSGCT) of the testis were treated by
inguinal orchidectomy and intensive follow-up only. Assess-
ment included measurement of serum alphafetoprotein and
beta HCG (tumour markers) and chest X-ray monthly for 1
year, then 2 monthly for 1 year, with CT scans of abdomen
and chest repeated 3 monthly for the first year and 6
monthly for the second year. Median follow-up was 33.5
months (range 5-87 months). Relapse occurred in 12 patients
(33.3%) at a median of 7 months (range 2-28 months). A
further patient developed a pure seminoma in the other testis
at 15 months and another had a para-aortic mass detected
on CT scan at 15 months. Laparotomy was performed and
histology revealed a differentiated teratoma. Elevated
markers were of limited importance in relapse detection
confirming the need for close clinical and radiological
follow-up. Of 9 histological factors examined in the primary
tumour only the presence of lymphatic invasion was asso-
ciated with a significantly higher relapse rate. All patients
were treated at relapse with cis-platinum based chemo-
therapy. Four underwent surgery in addition, 2 before and 2
after chemotherapy. Eleven were rendered disease free but 4
had a second relapse. One patient has died, one is alive with
disease in fourth relapse, and 10 are disease free. Chemo-
therapy failed to cure 6 patients who had relapsed, but bulk
of disease was not a factor. Despite the good overall result
reported here, optimal post-orchidectomy management of
stage I disease remains to be defined.
Expression of HMFG2 antigen in small cell carcinoma of
the lung: Relationship to prognosis
F.G. Hay, R. Milroy2, L.W. Adams', S.G. Allan'
& R.C.F. Leonard'
'I1mperial Cancer Research Fund Medical Oncology Unit,
Department of Clinical Oncology, Western General Hospital,
Edinburgh; and 2Cancer Research Campaign Department of
Medical Oncology, Glasgow, UK.
Despite the use of modern chemotherapy, long-term disease-
free survival can only be expected in approximately 10% of
patients with small cell lung carcinoma (SCLC), even includ-
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identify the group of patients with better prognosis so that
appropriate therapy can be chosen at the outset.
Recently we reported an inverse association between
HMFG2 antigen expression and survival in SCLC patients
(Allan et al., Br. J. Cancer, 56, 485, 1987). We have now
extended the preliminary study of HMFG2 expression in
pre-treatment bronchial biopsies to include a further 21
patients, making a total of 52 tumour specimens. As before,
formalin fixed, paraffin embedded material was studied using
a standard immunoperoxidase (PAP) staining procedure
following enzyme digestion of the tissue sections.
Overall, median survival was 8 months for those express-
ing HMFG2 antigen compared with 11 months for those
who were negative (P<0.01 Mann-Whitney U). In the
group of patients with limited disease (n=40), the same
statistical difference was apparent with median survival of 8
months in 22 patients who were positive for HMFG2 and 12
months for the 18 patients who were negative (P<0.01). The
value of HMFG2 as a prognostic marker merits study in a
wider assessment of pre-treatment prognostic variables.
Survival of patients with poor prognosis myeloma
D. Dodwell & I. McGill
Department of Medical Oncology, Torbay Hospital,
Torquay, S. Devon, UK.
Retrospective analysis of 133 patients with multiple myeloma
treated at our district general hospital over the last 14 years
was undertaken.
All patients presenting with stage 3A (13 patients) or stage
3B (24 patients (with renal impairment)) disease, according
to the staging system of Durie & Salmon (Cancer, 36, 842,
1975) were treated with a four drug chemotherapy regimen,
given monthly and using: vincristine, 1.4mgm-2 (max.
2mg), cytosine arabinoside, 150mgm2, cyclophosphamide
600mgm-2, all given on days 1 and 8 by i.v. bolus injection
and prednisolone 30mgm-2 orally on days I through 8,
along with standard supportive measures.
Of these 37 patients 14 died early in treatment prior to
receiving two courses of chemotherapy (in the first 2 months
after diagnosis).
Comparison of patient groups suggests that if patients
with stage 3A or 3B myeloma survive this 2 month period
then their survival thereafter is the same as the prognosti-
cally more favourable groups.
This we feel favours the use of intensive supportive
therapy in the management of patients who present with
poor prognosis myeloma, and we would advocate the use of
combination regimens which can be safely used in the
context of renal impairment, and which achieve rapid
tumour kill.
CMPP chemotherapy for intermediate and high grade non-
Hodgkin's lymphoma in the elderly
S.W. Watkin & J.A. Green
University of Liverpool Department of Radiation Oncology,
Clatterbridge Hospital, Bebington, Wirral, Merseyside
L634JY, UK.
The CMPP regime was developed for the treatment of
intermediate and high grade non-Hodgkin's lymphoma stage
II-IV in elderly and poor performance status patients in
whom doxorubicin containing regimens would be too toxic.
Twenty-one patients (9M: 12F) aged 52-79 mean 70 years,
have been entered onto the study. There were 12 high and 7
intermediate grade (NCI Working Formulation) and 2 myco-
sis fungoides. Eighteen of 21 were stage IV and 6/16 had
marrow involvement but no patient was leukaemic. Twelve
(51%) had received prior treatment at a mean of 3.3 years
before CMPP: 5 radiotherapy, 2 chemotherapy and 5 with
both. Patients received chlorambucil 10mgd-1 dI-O0, mito-
zantrone l0mgm-2 i.v. dl, procarbazine 150mgd-1 dl-10
and prednisolone 40mgd-1 dl-10, q21-28d. The mean
number of courses given was 3.7 and the mean cycle time
was 30d. Of 16 evaluable patients there were 6CR, 6PR,
4SD (overall RR 75%). Responders received a mean of 4.7
cycles against 2.4 in non-responders but there Was no
significant difference in cycle time (31 vs. 21 d). Median
follow-up is 4m and there have been 7 deaths at 0-11 m (2
early deaths in whom toxicity may have been contributory).
Median survival is 11 m. Three patients developed neutrope-
nic fever and 2 required transfusion but grade III/IV alope-
cia and vomiting were not seen. Sixteen of 78 courses were
deferred in 9 patients and procarbazine was omitted after the
first or subsequent cycles in 6 patients due to rash in 4 and
myelosuppression in 2. The CMPP regime produces an
acceptable response rate in this poor prognosis group with a
median survival of 11 m. The dose limiting toxicity is
haematological.
CAPE/PALE salvage chemotherapy in relapsed Hodgkin's
disease
D.H. Jones, J.M.A. Whitehouse & G.M. Mead
CRC Medical Oncology Unit, Southampton General
Hospital, Southampton S094XY, UK.
Since 1/84 16 patients (11 male, 5 female, age range 18-73
years, median 28 years) with poor prognosis relapsed
Hodgkin's disease (HD) (<1 year post chemotherapy) have
been treated with CAPE (cyclophosphamide 600mgm 2 i.v.
dl; adriamycin 50mgcm-2 i.v. dl; adriamycin 50mgcm-2
i.v. dl; etoposide, either 500mgm 2 p.o. given over d2-5 or
250mgm-2 i.v. dl) and PALE (CCNU 80mgm-2 p.o. dl,
with adriamycin, etoposide and prednisolone as above) given
as alternating cycles at 21 day intervals for 6 cycles. At
initial diagnosis 13 patients had NSHD, 3 MCHD; 5
patients were stage II, 11 stage III and I stage IV; 10
patients had B symptoms. Twelve patients had received prior
chemotherapy only, 4 radiotherapy and chemotherapy, 6
having achieved a CR lasting 2-12 mo, median 4/12, 7 a PR
and 3 progressive disease on therapy immediately prior to
CAPE/PALE. All patients had relapsed at previously
involved sites and at new sites in 3. The mean number of
cycles of CAPE/PALE administered was 5.5 (range 1 to 7).
Eight patients achieved a CR of whom 4 remain free of
disease at 16, 31, 33 and 42 mo, and 3 a PR an overall
response rate of 69%. Toxicity has been moderate. There
were 8 episodes of neutropaenic fever, two of dermatomal
HZV and one each of axillary cellulitis, infected central
venous catheter, acute myocardial infarction (AMI) and
cryptosporidial infection. There were no treatment related
deaths. Treatment was delayed in 9 patients on 16 occasions
and dose reductions made in 10 patients in 31 out of 86
cycles given, in 1 patient initially due to thrombocytopaenia
and later AMI and in 9 due to neutropaenia.
CAPE/PALE is effective as salvage chemotherapy in
relapsed Hodgkin's disease. Results are at least as good as
alternative regimens with acceptable toxicity and fewer
injections.
CHLVPP chemotherapy in advanced Hodgkin's disease
J.M.A. Whitehouse, C.J. Williams, J. Sweetenham,
D.H. Jones & G.M. Mead
CRC Medical Oncology Unit, Southampton General
Hospital, Southampton S094XY, UK.
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(HD) were treated with chlorambucil 6mgm-2 (max 10mg)
p.o. dl-14; vinblastine 6mgm-2 (max 10mg) i.v. dl and d8.
Procarbazine 100mgm-2 (max 200mg) p.o. dl-14; and
prednisolone 40mg p.o. dl-14, at monthly intervals and a
mean of 5.7 courses were administered. No patient received
chemotherapy (CT), 12 had relapsed after radiotherapy
(RT). Five patients received combined CT and RT for bulky
mediastinal disease. Forty patients were male and 14 females
(age range 15-73 years, mean 29). Sixteen patients were stage
II, 27 stage III and 11 stage IV. Twenty-nine patients had B
symptoms. Forty-two patients had NSHD, 6 MCHD and 6
LPHD. Mean follow-up time from completion of CT is 42
months (range 10-90). Forty-two (77.8%) patients achieved
CR with 33 (61.1%) in continuous CR at a mean follow-up
of 44 months (range 10-90). Ten patients (18.5%) died
during follow-up, 1 with no clinical evidence of HD 59
months from CT, 1 during CT and 8 from HD. The regime
was generally easy to administer and well tolerated. A mean
of >90% of the planned dose of each drug was adminis-
tered. Five patients required cessation of one of the regime's
drugs and substitution with another agent because of side
effects. Three patients had mild neuropathy, 2 moderate
nausea, and no patient had alopecia. There were 3 episodes
of neutropaenic fever, one of pneumococcal pneumonia and
one of disseminated HZV. One patient died during CT from
legionella pneumonia. Treatment was delayed in 8 patients
on 10 occasions, 1 due to poor compliance and in 9 due to
neutropaenia.
'PACET' intensive chemotherapy (CT) for relapsed
lymphoma
A phase I study of sequential recombinant interferon gamma
(IFN-G) and recombinant interleukin-2 (rIL-2) in patients
with solid tumours
J. Wagstaff, S.H. Goey, R.L. Scheper, J.B. Vermorken,
J.J.M. van der Hoevan & H.M. Pinedo
Free University Hospital, Amsterdam, The Netherlands.
Both rIFN-G and rIL-2 have shown anti-tumour activity in
single agent phase I studies. In vitro studies have demon-
strated synergistic anti-tumour activity. T cells activated by
rIFN-G developed maximal proliferative responses to rIL-2
after 4 days exposure. This study was designed to determine
the maximally tolerated dose and optimum immunomo-
dulatory doses (OID) of 5 daily i.v. bolus (over 15 min)
injections of rIL-2 following 5 daily i.m. injections of rIFN-
G given in two doses (10 and 100pgm-2 day) 16 patients
have been entered and recruitment will be completed in
January 1988. Tumour types were: melanoma (4), renal
carcinoma (4), colon carcinoma (3), soft tissue sarcoma (2),
mesothelioma (2) and non small-cell lung (1). Nine patients
had no prior chemo- or radiotherapy. rIL-2 dose levels were
0.5, 1.0, 2.0 and 3.Omega(m)Um-2d-1. Tengm-2 of
rIFN-G gave minimal side effects and whilst 100pgm-2
gave more toxicity no unexpected problems arose. All 3
patients given 3.0mUm-2d-1 experienced WHO grade III/
IV toxicity (hypotension, fever and liver toxicity). Two
required intensive care management for hypotension.
2.0mUm-2d-1 plus lOugm-2 rIFN-G could be used for
phase II studies in an ordinary ward setting. So far no
objective tumour responses have been seen. A recommenda-
tion for phase II will depend on toxicity in the
100ygm-2d-1 rIFN-G arm and on the OID. Immunologi-
cal testing will be performed on stored frozen cells in order
to ensure assay standardisation (e.g., NK and LAK cell
assays).
J.J. McKendrick, J.M.A. Whitehouse & G.M. Mead
CRC Medical Oncology Unit, Southampton General
Hospital, Southampton S09 4XY, UK.
The outlook for patients with relapsed high and intermediate
grade NHL (WF) and multiply relapsed HD is dismal.
Evidence suggests marrow ablative CT and marrow rescue
may improve survival. 'PACET' is highly marrow suppres-
sive CT which can be given as repeated courses with
acceptable and manageable toxicity without marrow rescue.
Early results suggest activity in these patients. Sixteen
heavily pretreated patients with relapsed high or intermediate
grade NHL or HD were treated with CCNU 60mgm-2 p.o.
dl-2; cytosar 00 mgm-2 i.v. BD, VP16-213 l00mgm-2
i.v., 6-TG 80mgm-2 p.o. and prednisolone 40mgm-2 p.o.
all dl-5 repeated at d28. A mean of 1.9 courses (range 1-3)
were given to 14 evaluable patients with median age 46 years
(range 28-65). Ten had DLC, 1 immunoblastic and I small
non-cleaved lymphoma, 1 HD and 1 malignant histiocytosis.
All patients had shown at least PR to prior CT. Two
patients (14%) achieved CR and are disease free at 2 and 14
months. One patient had a PR lasting 6 months and is alive
at 24 months. Overall response is 21%. Two further patients
had stabilization of disease (s.d.) for 10 months prior to
progression, 1 remaining alive for 17 months. Nine patients
have died. CT was generally well tolerated with <50%
patients having mild nausea and vomiting. Marrow toxicity
was severe with 23/27 (85.2%) courses causing W.H.O. grade
4 neutropenia (NP) and 24/27 (88.8%) grade 4 thrombocyto-
penia. A mean of lOU plts and 5U blood were given per
patient. Nineteen of 27 (70%) courses were associated with
NP fever requiring antibiotics. One patient died of opportu-
nistic infection. The response and acceptable toxicity seen in
a conventionally refractory group of patients with this
regime warrants further investigation.
The effect of alpha-2 interferon on the pharmacokinetics of
ifosfamide
M.J. Lind1, J.M. Margison2, N. Thatcher'
& P.M. Wilkinson2
1CRC Department of Medical Oncology and 2Department of
Clinical Pharmacology, Christie Hospital and Holt Radium
Institute, Manchester M209BX, UK.
It has been shown in several xenograft models that synergy
exists between interferon and a wide variety of cytotoxic
drugs. The mechanism of this is unknown but it has been
speculated that interferon may alter drug biotransformation.
Interferon can inhibit cytochrome P450 which is important
in the biotransformation of ifosfamide to its active metabo-
lites. We therefore, decided to investigate the effect of alpha-
2 interferon on the pharmacokinetics of ifosfamide. Patients
with non small-cell lung cancer were given ifosfamide
1.5 gm-2 i.v. per day for 5 days during which serial blood
samples were taken for assay of ifosfamide levels. Two weeks
later they were started on alpha-2 interferon 3 million units
SC x 3/week for 2 weeks. During the second week, they were
given a second 5 day course of ifosfamide at the same dose
as before and further blood samples were taken to study
ifosfamide pharmacokinetics. The preliminary results are
shown below and do not indicate any great inhibition of
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Pre
Days 1 3 5
Clearance (mlmin 1) 102 147 175
t1/2 (h) 3.73 2.33 2.34
AUC (pghmml1) 510 336 316
Post IFN
Days 1 3 5
Clearance (mlmin1) 88 109 183
t1/2 (h) 4.15 3.80 2.40
AUC (yghmml) 562 412 289
The influence of treatment on survival from wel
differentiated thyroid carcinoma
D.J. Kerr1, N. Reed2, G.J. MacFarlane', P. Boyle'
& A.D. Burt3
1CRC Department of Medical Oncology and Departments of
2Radiation Therapy and 3Pathology, Western Infirmary,
Glasgow, UK.
Thyroid cancer is a relatively rare disease (age standardised
incidence rate of approximately 2/100,000 in Scotland) yet
there is data to suggest that it has been steadily increasing in
incidence over the past 15 years and following the recent
incident in Chernobyl it is widely predicted that there will be
a large number of excess cases across Europe over the next 3
decades. We have retrospectively analysed 495 cases of
thyroid cancer which were treated in Glasgow over the past
30 years and have confirmed, by multivariate analysis, that
the prognostic score defined by the EORTC cooperative
group is applicable to our patient group. We determined the
influence of treatment on overall survival in the well differ-
entiated thyroid cancer patients (199) using a Cox's pro-
portional hazards model to compare treatment subgroups
which were balanced according to prognostic score. In
summary, the type of thyroid surgery did not influence
survival; the addition of radio-iodine to surgery did not
influence survival; the addition of external beam radiation to
surgery and radio-iodine significantly worsened survival.
The effect of chemotherapy on CA125 immunohistochemical
expression in epithelial ovarian cancer
C.W.E. Redman, M. Bradgate, R. Rollason, C. Hilton,
P.A. Canney, F.G. Lawton, K.K. Chan, D. Luesley
& G.R.P. Blackledge
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Hospital, Birmingham, UK.
CA125 is a glycoprotein found on the surface of most
epithelial ovarian carcinomas (EOC), detected using a mur-
ine monoclonal antibody OC125. Within reactive tumours,
positive and negative cells are found to be intimately mixed
demonstrating tumour cell heterogenicity, which has import-
ant implications in tumour response. Changes in the histo-
logical appearance of tumours have been noted following
chemotherapy, possibly reflecting the eradication of chemo-
sensitive subpopulations of cells. Though serum CA125
levels have been shown to closely parallel tumour response,
the effect of chemotherapy on the proportion of cells
expressing CA125 within a tumour has not been studied.
Serum and histological material were obtained from 19
patients with histologically confirmed EOC, who had under-
gone primary and post-chemotherapy laparotomies. All
patients had had macroscopic residual disease at the end of
the first operation and had received either single agent or
combination platinum therapy. All patients had macroscopic
disease at the second operation though no patients had
progressed on treatment. Immunostaining was performed on
tissue sections from formalin-fixed paraffin embedded speci-
mens, using OC125 murine monoclonal antibody purchased
in kit form (CIS UK). CA125 positivity of the tissue sections
were assessed on the basis of intensity and consistency of
staining.
Pre-chemotherapy serum CA125 levels were markedly ele-
vated and significantly decreased during treatment. The
histological features of tissue obtained at the second ope-
ration were unchanged except in three cases of serous
cystadenocarcinoma in whom the tissue obtained from the
second operation appeared more differentiated. There was
no difference in immunostaining between primary tumour
and metastatic disease. Ninety-five percent (18/19) of the
tumours were CA125 positive. Positivity was observed for all
histololgical types, and in the serous sub-group, positivity
did not appear to be related to the degree of cellular
differentiation. CA125 expression in pre- and postchemo-
therapy specimens was not significantly altered in the major-
ity of cases. Six cases showed an increase (3) or a decrease
(3) in CA125 expression. Whilst a fall in serum CA125 levels
reflected a reduction in tumour bulk, there was no correla-
tion between falling serum CA125 levels and a reduction in
the degree of tissue CA125 expression. No significant asso-
ciation was noted between survival and change in CA125
positivity. Reduction in serum CA125 levels in responding
patients largely reflects a reduction in the tumour bulk as a
whole not specifically those cells that release CA125.
Phase I-II study of carboplatin vincristine methotrexate and
bleomycin (COMB) in carcinoma of the cervix
G.J.S. Rustin & E.S. Newlands
CRC Laboratories, Charing Cross Hospital, London W68RF
and Mount Vernon Hospital, Northwood, Middlesex, UK.
An objective response rate of 71% was obtained using a
combination of cis-platin 100 mgmi-2, vincristine 1 mgm-2,
methotrexate 300mgm-2 and bleomycin 30mg (POMB) in
24 patients with advanced squamous cell carcinoma of the
cervix (Br. J. Obstet. Gynaecol., 94, 111, 1987). To reduce
the toxicity of cis-platin, carboplatin was substituted at a
dose of 200mgm-2 to be given every 14 days with the other
drugs unchanged.
Twenty-four patients with squamous cell carcinoma of the
cervix were studied. Their mean age, performance status, site
of disease and percentage receiving prior radiotherapy were
similar to patients in our POMB study. Two patients
received one course of COMB, 8 had 2, and 14 had more
than 2 courses. Dosage reductions were made because of
renal impairment in 9 patients. Courses of chemotherapy
were only delayed because of myelosuppression in 4 patients.
Five patients had WHO grade 3 and 4 had grade 4
leukopenia, one had WHO grade 3 and 2 had grade 4
thrombocytopenia.
Two patients died from neutropaenic septicaemia, 1 died
from uncontrollable pelvic haemorrhage and 2 did not have
evaluable disease. Only 5 of the remaining 19 patients had a
partial response (26%, 95 confidence limits 45.7-6.38%).
Carboplatin as given in the COMB regimen appears less
effective than cis-plitin containing combinations for squa-
mous cell carcinoma of the cervix.THIRD ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS 273
Intraperitoneal treatment of human ovarian tumour
xenografts with liposome encapsulated muramyl-tripeptide
phosphoethanolamine (MTP-PE)
S.T.A. Malik, I. Hart & F. Balkwill
Imperial Cancer Research Fund, Lincoln's Inn Fields, P.O.
Box 123, London WC2A 3PX, UK.
Muramyl dipeptide (MDP) is a component of bacterial cell
walls, which activates macrophages in vitro to kill tumour
cells. In vitro, native MDP is rapidly excreted, and does not
induce a significant macrophage antitumour activity even in
high doses. To overcome this problem, a lipophilic derivative
of MDE, MTP-PE, has been incorporated in liposomes.
Systemically administered MTP-PE containing liposomes
have been shown to cause tumour regression of syngeneic
murine tumours (Fidler, Cancer Res., 45, 4714, 1985).
A study of liposome encapsulated MTP-PE in the treat-
ment of three human ovarian tumour xenografts (OS, Hu
and LA) in nude mice was conducted. Five days after
intraperitoneal instillation of xenografts, twice weekly injec-
tions of PBS, liposomes only (LP) or liposome encapsulated
MTP-PE were given for 4 weeks. The survival data in the
three xenografts are shown below:
Mean survival (days)
OS Hu LA
1. PBS 26.5 34.5 26
2. LP 37 61 28
3. MTP/PE > 130 >90 39
Liposome encapsulated MTP-PE significantly prolonged sur-
vival in all three models (P<0.01). In the Hu xenografts,
placebo liposomes were also associated with increased survi-
val. Further studies to characterise peritoneal cell popula-
tions and the possible involvement of Tumour Necrosis
Factor in these models are in progress.
A phase II evaluation of trimelamol (N2,N4,N6-
trihydroxymethyl-N2,N4,N6-trimethylmelamine) in stage III/
IV ovarian cancer
I.R. Judson, M.E. Gore, L.A. Gumbrell, K. Balmanno,
D.I. Jodrell, T.J. Perren, E. Wiltshaw, P. Blaked &
A'H' Calvert
Institute Cancer Research and Royal Marsden Hospital,
London and Sutton, Surrey, UK.
Trimelamol is an analogue of hexamethylmelamine which
does not require metabolic activation. A phase II study was
undertaken in patients with recurrent stage III/IV ovarian
carcinoma after promising activity had been observed in the
phase I studies. Forty-three patients were treated in this
study, of whom one was found to have an undifferentiated
sarcoma, and was therefore excluded from analysis. Thirty-
one of the 40 evaluable patients were stage III and 32 had a
WHO performance status of 0, 1 or 2. All patients had
undergone prior surgery, and chemotherapy with either cis-
platin (11/40), carboplatin (11/40) or both (18/40). Only 9
patients received prior radiotherapy. Patients were treated
with 800 mg m-2 for 3 consecutive days repeated every 3
weeks. However, 8 patients had dose reductions becaue of
low WBC nadirs (<2 x 1091-1), and 5 poor risk patients
(e.g. extensive abdominal/pelvic irradiation or extensive prior
chemotherapy) also had dose reductions. All dose reductions
were to between 600 and 700 mg m- 2 x 3. Ninety-six courses
of trimelamol were given, the median number of courses
received being three. The WBC nadir was similar to that
seen at the same dose in the phase I study, i.e. 3.4 x 109 1-1
(range 1.4-9.2 x 109 1-') with a median nadir day of 14
(range 6-26). The responses seen were CR: 1; PR:2; MR:4;
NR/PD:31 and NE:2 giving an overall response rate
(CR+PR) of 8% for assessable patients. This is disappoint-
ing when compared to the 23% (5 PR/22) response rate seen
in the patients with refractory ovarian cancer treated at over
600mgm 2 x 3 in the phase I study, although it does
confirm that trimelamol has some activity in this usually
refractory group of patients.
Ifosfamide (I) and ifosfamide+cis-platin (P) chemotherapy
for advanced cervical carcinoma
R.E. Coleman, J. Clarke, M.L. Slevin, E. Wiltshaw &
P.G. Harper
On behalf of The London Gynaecology Oncology Group,
UK.
The use of chemotherapy is increasing in cervix cancer for
both palliation of advanced or relapsed carcinoma of the
cervix and as part of primary treatment in poor risk patients.
The optimum drug or combination of drugs is not defined.
However, like others, we have found I to be an active drug
and report our experience with I based first-line chemother-
apy in two consecutive series of patients.
Seventy-one patients received I 1.5 gm-2 daily x 5 with
mesna every 3 weeks. Thirty-nine patients received in addi-
tion P 50mgm 2 on day 1. Sixty-two patients had been
previously irradiated. Of 30 evaluable patients receiving I
alone 12 (40%) responded (6 CR and 6 PR, median duration
21 months [range 3-48+ months]); and of 31 receiving I+P
(39%) responded (2 CR+10 PR, median duration 7 months
[range 5-12 months]). In both series similar response rates
were seen in both irradiated and non-irradiated sites.
The major toxicity was bone marrow suppression with 4
(12%) receiving I alone and 10 (26%) I+P developing WHO
grade IV leucopenia. All patients developed alopecia and
nausea and vomiting was severe (WHO grade III or IV) in
10 (30%) receiving I and 16 (41%) I+P.
I is a useful agent in this disease and a few durable
remissions were seen with I alone. The addition of P does
not appear to add to the response frequency but increases
toxicity. Furthermore durable remissions have not been seen
following I+P.
High dose (HD) carboplatin (JM8) for stage IV ovarian
carcinoma: A preliminary analysis of response, toxicity and
survival
T.J. Perren, M.E. Gore, I. Fryatt & E. Wiltshaw
Gynaecology Unit, Royal Marsden Hospital, Fulham Road,
London SW3, UK.
Stage IV ovarian carcinoma (OC) has a poor prognosis. Our
previous experience with cis-platinum 100mgm-2 in 19 such
patients gave a 61% response rate, a median survival of 13
months, and only one patient alive beyond 3 years (Wiltshaw
et al., J. Clin. Oncol., 4, 722, 1986). The dose limiting
toxicity of JM8 is haematological which makes it attractive
for use in high dosage with full support.
In an attempt to improve survival of stage IV OC we
treated 38 patients with HD JM8 every 4-5 weeks (14
patients in a dose escalation study - (mgm-2) 520 (5) 650
(6), 800 (3) patients - and 24 patients at I gm-2). Median
age 55 years (39-67). WHO PS 0 (12), 1-2 (20), 3-4 (6)
patients. Residual bulk (cm) <2 (4), 2-5 (8), >5 (26)
patients. Response, relapse and median time to relapse
(MITR) as follows (3 of the 1 gm-2 patients were not
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Patients CR PR
Dose esc. 14 4 (2 path) 3
1gm-2 21 4 (2 path) 9
Overall Relap. MITR
Dose esc. 7 (50%) 6 11 mos
1 gm-2 13 (62%) 5 15 mos
At 1 gm-2 the main toxicity was cumulative myelo-
suppression and 8 patients had treatment stopped as a result.
Eleven patients had dose reductions due to a reversible fall
in GFR. Main toxicities as shown.
WHO grade 0 1-2 3 4
Leukopenia 0 2 8 4
Thrombocytopenia 0 0 3 14
Infection 11 7 4 0
Nausea and vomiting 0 19 3 0
Median survival for dose esc. and I gm-2 patients was 14
and 21 months respectively.
We feel that HD JM8 compares with our previous exper-
ience and is worthy of further study.
Identification of patients at high risk of recurrence after
surgical management of stage IB and IIA cervix cancer
E.J. Burton1, N. Saunders2, M. Patterson2
& G. Blackledgei
'CRC Clinical Trials Unit, Queen Elizabeth Hospital,
Birmingham; and 2The Northern Hospital, Sheffield, UK.
Stage specific 5-year survival for treated cervix cancer remain
unchanged. In the West Midlands 65% of patients present
with stage I disease with a 5-year survival in this group of
around 80%. Thus around 20% of patients will present with
recurrent disease. In this group of patients 1 year survival is
less than 15%. We present a peliminary analysis of 120
surgically treated patients with stage IB and IIA cervix
cancer. The aims of the study were: to compare data from
patients treated in our practice with published data, to
identify and characterize patients at high risk of recurrence
who might benefit from adjuvant therapy and to develop a
prognostic score which may be applied prospectively to
identify these patients prior to conventional therapy. Case
records of all patients treated with radical hysterectomy for
stage IB/11A cervix cancer were examined. Demographic
histologic, treatment, relapse and survival data were
extracted. In 23 of 120 cases recurrence occurred. In 3 cases
recurrence was central pelvic, in 18 cases pelvic sidewall, and
in 2 cases distant metastases. There was no correlation
between recurrence and age at operation, stage, cell type or
degree of differentiation. There was a significant association
between recurrence and the presence of lymphatic or vascu-
lar invasion and pelvic or para-aortic node metastases. It
was not possible on the basis of this retrospective analysis to
comment on tumour volume. Lymphatic/vascular permea-
tion and lymph node metastases are shown to be associated
with a high risk of recurrence. Further research to develop a
sensitive and specific scoring system to predict recurrence
and identify patients who may benefit from adjuvant treat-
ment is underway.
Sequential cis-platin/cyclophosphamide chemotherapy and
abdomino-pelvic radiotherapy in the management of advanced
ovarian cancer
J.A. Green, R.D. Errington, S. Myint, A.J. Slater
& H.M. Warenius
CRC Department of Radiation Oncology, Clatterbridge
Hospital, Wirral, Merseyside L634JY, UK.
Following the high response rates achievable with combi-
nation chemotherapy in advanced ovarian carcinoma, this
pilot protocol employs the addition of abdominopelvic
radiotherapy to control residual small volume disease. Forty-
six patients with advanced ovarian cancer (6 stage I, 5 stage
II, 25 stage III and 9 stage IV) were treated with 5 cycles of
cis-platin 80mgm-2 and cyclophosphamide I gm-2, given
IV every 28 days. All patients were ECOG performance
status 0-2 and of 41 evaluable patients for response to
chemotherapy there were 31 CR (72%), 4 PR (9%), 4 PD
and 2 SD, based on clinical criteria in 23, and second look
procedures in 18. Twenty-four patients in clinical or patholo-
gical complete remission then received abdominal radio-
therapy to a dose of 25Gy in 25 fractions with posterior
renal shielding at 15 Gy followed by a pelvic boost of 20 Gy.
Twenty-four patients in CR have completed sequential
chemotherapy and radiotherapy. Eighty-five percent of
patients received more than 75% of their planned chemo-
therapy, and the pelvic boost was omitted in 2 patients and
suspended in 5 on account of myelosuppression. The median
survival of the stage IV patients was 12 months, but has not
been reached in those patients achieving a clinical or patho-
logical CR. Of those completing both treatments 75%
remain alive and free of disease at a median follow-up of 30
months. In the 15 patients with stage III/IV disease with
moderate or poor histological grade given chemotherapy and
radiotherapy, the actuarial 2 year survival was 67%. This
intensive approach is feasible at the doses of chemotherapy
and radiotherapy stated, and achieves a high relapse free
survival.
An open pilot study of the 5-HT3 antagonist, BRL43694, an
effective antiemetic in refractory highly emetogenic cytotoxic
drug induced emesis
L.A. Gumbrell1, C. Qualmann1, T.J. Perren1,
G. Forgeson1, A.H. Calvert1, S. Thompson2
& W.G. Rapeport2
lInstitute of Cancer Research and Royal Marsden Hospital,
Surrey and London; and 2Beecham Pharmaceuticals
Research Division, Harlow, Essex, UK.
BRL43694 is a selective 5-HT3 receptor antagonist which
exhibits potent antiemetic activity in ferrets (Boyle et al., Br.
J. Pharmacol., 91, Proc. Supp. 418 p, 1987). Fourteen
patients were treated who had had severe nausea and
vomiting (N/V) refractory to conventional antiemetics
(usually metoclopramide/lorazepam) on previous courses of
treatment. They received 20 jugkg-I (1 patient) and
40pgkg-1 (13 patients) of BRL43694 given as a 30min i.v.
infusion, starting 30min post cytotoxic drug treatment. N/V
were assessed on 4-point global scales, nausea was also self-
assessed on a visual analogue (VA) scale and emetic episodes
were recorded for 24 h after chemotherapy. Results were: cis-
platin (75-100mgm2 9 patients) 1 patient had no NV, 2
were free from NV for 12-18 h, 3 had N/V but less than on
previous courses and 3 all with anticipatory N/V, derived no
benefit. Carboplatin (200mgm-2, 3 patients) (+methotrexate
and vinblastine): all 3 patients had no M/V. Trimelamol
800 mgm-2 x 3, 2 patients): both patients had no benefit.
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with nausea. Using global scales 2 patients reported mild
nausea at 4h and 6 patients had moderate nausea at 24h.
Using VA scales moderate/severe nausea at the time of
dosing was seen in 6 patients which persisted to 24h in 4.
The only side effect noted was a mild/moderate headache
which occurred in 5 patients. No other adverse effects were
noted. Haematology and biochemistry values stayed within
normal limits and the ECG (monitored for 30min) and
blood pressure (monitored for 6h) were unaffected. In
summary 9/14 patients with severe N/V refractory to conven-
tional antiemetics experienced benefit from low doses of
BRL46394 compared to their previous courses. Six of these
had a substantial improvement. Patients with anticipatory
vomiting did not benefit from the treatment schedule used.
Antiemetic activity of BRL43694, a selective 5-HT3
antagonist in cancer chemotherapy
J. Cassidy', C. Lewis', W.G. Rapeport2, V. Raina3,
M. Soukop3, E.M. Rankin1 & S.B. Kaye1
IDepartment of Oncology, University of Glasgow; 2Beecham
Pharmaceuticals, Harlow, Essex; and 3Glasgow Royal
Infirmary, UK.
BRL43694 is a new selective 5-HT3 antagonist, with promis-
ing preclinical antiemetic activity. Twenty patients receiving
a variety of emetogenic cytotoxics (including cis-platin in 5)
were given BRL 43694 40jgkg-1 in this open study. The
antiemetic was administered as a single 30min i.v. infusion
between 0 and 6 h after the first course of chemotherapy in
successive groups of patients. Standard antiemetics were
given for all subsequent courses. Patients completed visual
analogue scales (VAS) of nausea, and trained observers
assessed nausea, vomiting and adverse effects 4-hourly for
24h. Seven patients experienced neither nausea nor vomiting.
Four patients recorded no nausea on VAS, but were noted
by observers to have mild nausea without any vomiting. In 9
patients mild to moderate nausea and vomiting occurred:
usually more than 9-12 h after antiemetic administration.
Fourteen patients expressed a preference for BRL 43694 over
standard antiemetics given with the second course of chemo-
therapy. In 4 of the patients of whom BRL 43694 was
delayed until 4-6 h after chemotherapy, vomiting had
already begun to occur, in each case immediate termination
of vomiting occurred when BRL43694 was infused. There
was no clear relationship between interval from chemo-
therapy to BRL 43694 administration and antiemetic effi-
cacy. Mild sedation was noted in 6 cases, though the
relationship to drug administration was unclear because of
concurrent use of hypnotics and analgesics. No other adverse
effects were observed. This study shows BRL 43694 to be an
effective and well-tolerated antiemetic. Studies continue to
define optimum dosage schedules.
Phase I-II trial of UFT in the treatment of advanced
colorectal gastric and breast cancer
S.T.A. Malik, P. Clark, R. Osborne, D. Talbot, P. Wilson,
P.F.M. Wrigley & M.L. Slevin
ICRF Department of Medical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
UFT is a combination of uracil and the 5-fluorouracil (5-
FU) analogue Futraful (1-(2-tetrahydrofuryl)-5-fluorouracil).
Studies in vitro and in experimental tumour models have
shown that the cytotoxic effect of fluoropyrimidines can be
potentiated by purines and pyrimidines (Fukii et al., Gann,
69, 763, 1978). The mechanism of this effect may be related
to the increased intratumoral levels of 5-fluorouracil
achieved with concomitant administration of uracil (Taguchi
et al., Cancer Chemother., 5, 1167, 1978). Futraful has
greater bioavailability than 5-FU after oral administration. It
is metabolised to 5-fluorouracil and at least four other
compounds (Au, Cancer Treat. Rep., 63, 343, 1979). As it
has a long half-life (6-16h), it may act as a slow-release
preparation of 5-FU. A phase I-II study of oral UFT
(12mgkg-1 day, max. dose 600mgday-1) given as three
divided doses is in progress, 33 patients with advanced
colorectal cancer, 9 with advanced stomach cancer, 11 with
advanced breast cancer have been treated. The results in the
currently evaluable patients are tabulated below.
Previous
N chemotherapy PR CR
1. Colorectal cancer 26 3 3 0
2. Stomach cancer 6 0 0 0
3. Breast cancer 8 5 1 0
Partial responses in colon cancer patients lasted 9, 16 and 60
weeks. Myelosuppression was not seen and non-
haematological toxicity was minimal. Conclusion: Oral UFT
is well tolerated but the study suggests that its antitumour
activity is not substantially different from that of
5-fluorouracil.
Phase II study of methyl acetylenic putrescine in colorectal
carcinoma biochemical effects
J. Carmichael1, D. Khayat1, C. Jacquillat', G. Tell1,
A. Skillen' & A.L. Harris1
Departments of 1Clinical Oncology and 2Biochemistry,
Newcastle upon Tyne, UK; 3Medical Oncology, Hosp.
Salpetriere, Paris; and 4Merrell Dow Research Institute,
Strasbourg, France.
Sixteen patients with advanced colorectal carcinoma were
treated with the ornithine decarboxylase inhibitor methyl
acetylenic putrescine (MAP) 250mgtds for 8 weeks. There
were 13 male and 3 female patients with a mean age of 58.8
years. Ten patients had hepatic metastases and 5 pulmonary
metastases. Investigations performed included weekly FBC,
U+E, LFT's and creatinine clearance. Urine was assayed
weekly: for measurement of urinary protein, alanine amino-
peptidase and N-acetyl f-glucose aminidase (NAG). Urinary
excretion of decarboxylated S-adenosyl-L-methionine (dC-
SAM) was measured as an index of biochemical activity. No
therapeutic responses were seen, but stable disease was
observed in 6 patients. At this dosage the drug was relatively
well tolerated with mild epigastric pain and general malaise
most frequently reported. In a sub-group of patients, the
mean level of dc-SAM. prior to treatment was
1,393nmol24h-1; 3,395 at week 1; 5,565 at week 2; and
8,126 nmol24h 1 at week 3, representing a 6.7-fold increase.
Urinary NAG and creatinine clearance results indicated
transient alterations of renal function in 2 patients on MAP.
MAP had minimal haematological toxicity, although 1
patient had transient thrombocytopoenia, at 6 weeks, which
was not clinically significant. In 6 patients following 4 weeks
MAP therapy there was a decrease in total lymphocyte
count.
MAP 250mgtds was well tolerated and caused the
expected biochemical effect. Despite the lack of activity in
this resistant tumour type, this drug is worthy of further
study in view of its interesting biochemical activity, although
close attention should be paid to renal function in these
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A phase II study of carboplatin in adenocarcinoma of the
oesophagus
A. Steel', M.H. Cullen', P. Robertson' & H.R. Matthews'
'East Birmingham Hospital and 2Queen Elizabeth Hospital,
Birmingham, UK.
Carboplatin has been evaluated as a single chemotherapeutic
agent in 15, previously untreated, male patients with adeno-
carcinoma of the oesophagus. Ages ranged from 49 to 72
(median 62) and all tumours except one were in the lower
thoracic oesophagus. The patients were all of good perfor-
mance status (WHO 0 or I). Patients were staged with
thoraco-abdominal CT scan before chemotherapy and again
after two courses for response assessment. Pre-treatment
radiological staging was as follows: One case T1, 11 cases
T2, 2 cases T3; 4 cases had N1M1 disease in addition.
Carboplatin was used at a dose of 400mgM-2 i.v. infusion
over 30 min repeated after 28 days. Twelve patients are
currently evaluable for treatment response. Nine patients
have shown no change in the size of their primary tumour
and 3 have shown progression. One patient died from
gastro-intestinal haemorrhage after the second course and 2
patients have not completed therapy. Eight patients have
undergone resection of their tumours following chemother-
apy, with one post-operative death. Toxicity was mild and
manageable. Nausea and vomiting WHO grade I was
recorded in 6 cases and WHO grade II in 5 cases. Four
patients experienced no nausea or vomiting. Grade I haema-
tological toxity on day 28 affected 7 patients with 1 or both
courses and grade II or III toxicity affected 1 patient each.
There were no cases of severe, permanent nephrotoxicity.
Carboplatin in this dosage and schedule is ineffective as a
single agent in adenocarcinoma of the oesophagus.
Clinical and preclinical pharmacokinetic studies with 1-(4-
carboxyphenyl)3,3-dimethyltriazene (CB10-277)
B.J. Foster1, D.R. Newell1, J. Carmichael2, A.L. Harris2,
L.A. Gumbrell1, D.E.V. Wilman1 & A.H. Calvert'
lInstitute of Cancer Research, Sutton, Surrey; and
2Newcastle General Hospital, Newcastle upon Tyne, UK.
CB1O-277 is an analogue of dacarbazine (DTIC) which is
currently undergoing phase I clinical evaluation. In experi-
mental systems CB1O-277 and DTIC have equivalent anti-
tumour efficacy and CB1O-277, like DTIC, requires
metabolic activation in order to display activity. As part of
the preclinical and early clinical evaluation of CB1O-277 the
pharmacokinetics of the drug in patients and mice have been
compared. In mice, following a maximum tolerated dose
(750mgm-2 i.v.), CB19-277 was cleared monophasically
from plasma (25 mlmin m-2, t2 32 min). In addition to
CBIO-277 one major and two minor metabolites were found
in plasma using HPLC analysis. The major metabolite was
sensitive to hydrolysis by glucuronidase yielding CBIO-277
whilst one of the minor metabolites was identified by HPLC
as the monomethyl derivative of CB1O-277. Monomethyl
CB1O-277 is the proposed active metabolite of the drug and
the levels observed in plasma (>50MM for I h) are sufficient
to explain the antitumour activity seen with CB1O-277 in
mice. In an ongoing phase I study 12 patients have received
24 courses of CB1O-277 with doses escalated from 80 to
1,350 mgm-2 (i.V. bolus). Toxicities have been mild, i.e.
nausea and vomiting WHO grade I 3/24, grade 11-III 3/24
and rashes grade I 1/24, grade II-III 2/24. No haemato-
logical toxicity has been seen. Pharmokinetic analyses have
been performed on 20 courses. CB10-277 plasma clearance
(74+30mlmin-1 m 2, mean+s.d.) was biphasic (terminal t1/2
79+36min). Two major CB10-277 metabolites have been
detected in human plasma. Of these, one is the glycine
conjugate of CB1O-277 whilst the other has HPLC properties
similar to the glucuronidase sensitive metabolite seen in mice
and is the major plasma metabolite following doses of
>600mgm 2. In addition, at 900 and 1,350mgm 2, mono-
methyl CB1O-277 may be present (levels <10,M). These
studies have shown that, qualitatively, CB1O-277 metabolism
is similar in mice and in patients. Thus clinical antitumour
activity may be anticipated and has in fact been observed
with 1 minor and 2 partial responses out of 4 melanoma
patients treated.
Methotrexate (M), vinblastine (V), adriamycin (A) and cis-
platin (C) for advanced bladder cancer
C.J. Twelves1, J.A. Clarke1, R.E. Coleman1,
R. Stuart-Harris1, T. Oliver2 & P.G. Harper'
1Clinical Oncology Unit, Guy's Hospital and 2The London
Hospital, Whitechapel, London, UK.
Bladder cancer is generally not considered to be a chemo-
sensitive tumour, but recently a high response rate and
prolonged survival have been reported in patients with
advanced bladder cancer treated with M-VAC chemotherapy
(Sternberg et al., J. Urol., 133, 403, 1985). We undertook a
phase II study to confirm these results.
Treatment was M 30mgm 2 i.v. days 1, 15 and 22; V
3mgm-2 i.v. days 2, 15 and 22; A 30mgm-2 i.v. day 2; and
C 70mgm-2 i.v. day 2. Maximum of 6 cycles was given at 4
weekly intervals. If the creatinine clearance was under
40 mlmin-1, C was withheld (3 patients) or carboplatin was
given (4 patients) at a dose adjusted for renal function.
Patients were assessed after 3 and 6 cycles of chemotherapy.
Twenty-six patients with transitional cell carcinoma (2
advanced primary cancer alone and 24 metastatic disease)
were treated. Thirteen had progressed after DXT to the
primary site and 2 had received prior chemotherapy. Median
age was 64 years (range 34-75), 22 male and 4 female.
Median ECOG status at entry was 2 (0=5 patients, 1=7
patients, 2=5 patients, 3 =9 patients).
Of the 26 patients assessable to date, 3 had complete
response and 10 partial response. The overall response rate
was 13/26 (50%) and median response duration was 30
weeks. Responses was seen in the bladder (44%) including 3
patients who had progressed after DXT, lymph nodes (68%),
lung (37%) and liver (25%). There were 2 early deaths (1
toxic and 1 sudden at home). All patients are evaluable for
toxicity; 11 had WHO grade III or IV vomiting and 16 had
WHO grade III or IV myelosuppression.
M-VAC chemotherapy is effective in this group of poor
prognosis patients with advanced bladder cancer. Toxicity is
significant, but M-VAC gives useful palliation for many
patients.
Haematological recovery after high dose cyclophosphamide
(CTX) and autologous bone marrow transplantation (ABMT)
C.J. Twelves', R.L. Souhami2, P.G. Harper1
& A. Goldstone3
1Clinical Oncology Unit, Guy's Hospital and Departments of
2Oncology and 3Haematology, University College Hospital,
London, UK.
ABMT is widely used to reduce myelosuppression after high
dose alkylating agent, but often with little firm evidence of
its value. We have studied haematological recovery in 31 fit,
previously untreated small cell lung cancer patients receiving
high dose CTX with ABMT.
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200 mgkg-1 i.v. over 4 successive days. Patients received
either a single cycle of high dose CTX with ABMT or 2
cycles of CTX with ABMT. Bone marrow was harvested
before initial chemotherapy in all patients and reinfused after
each cycle of high dose CTX. In most patients ABMT was
48 h after completing chemotherapy, designated day 2. In an
attempt to evaluate ABMT, reinfusion was delayed to day 4,
6 or 8 after the first cycle of CTX 200mgkg-1 in some
patients.
Treatment groups and duration of myelosuppression were
as follows:
Neutrophils Platelets
No. ABMT<500x 0 1-1 <500x101-l
Chemotherapy pts (day) (days) (days)
CTX 160mgkg-1
(cycle 1) 7 2 9.6 1.7
CTX 200mgkg-1 11 2 10.6 6.7
(cycle 1) 3 4 12.0 4.8
8 6 13.7 9.3
2 8 14.5 9.5
CTX 200'mgkg-1
(cycle 2) 11 2 14.8 14.5
ABMT contributes to haematological recovery when CTX
200 mgkg-1 is given over 4 days. However, myelo-
suppression is more prolonged after cycle 2, suggesting
recovery is more dependent on ABMT after the second cycle
of CTX, or that there is residual stromal damage after initial
chemotherapy.
Oral idarubicin in the treatment of acute myelogenous
leukaemia (AML) and chronic myeloid leukaemia (CML)
accelerated phase/blast crisis
S.T.A. Malik, J. Tucker, W. Brace, A.Z.S. Rohatiner
& T.A. Lister
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, West Smithfield, London ECIA 7BE, UK.
Idarubicin is a daunorubicin analogue that has been demon-
strated to have antileukaemic activity after intravenous
administration (Dagnestini et al., Cancer Res., 45, 1408,
1985). It is also active when given orally. A phase I-II study
of oral idarubicin (25 mgm-2 day-I for 3 days) was con-
ducted in patients with AML and CML in the accelerated
phase or blast crisis.
The details of the AML patients are as follows: Total
no.= 14, previously treated= 12 (4 relapsed, 8 resistant),
previous myelodysplasia= 5, mean age 58 (range 18-81),
median white cell count= 72.5 x 1091-1, median blast
count=65 x 109 1-l.
The CML group comprised: 2 myeloid blast crisis, 1
megakaryocytic/erythroid blast crisis, and 3 accelerated
phase, mean age 49 (range 32-60), median white cell
count= 184 x 109 l -I (range 28-340 x 1091-1).
No complete remissions were seen. The first course of
idarubicin was associated with a decrease in both the
peripheral wbc and blast count by day 4 in all patients.
Nadir counts were reached at 4-7 days in AML patients,
and 14-33 days in CML patients. All responses were tran-
sient, with an eventual rise in peripheral white cell and blast
counts. One patient with AML received 3 courses of idarubi-
cin before becoming resistant, 5 patients with CML received
2 to 6 courses of idarubicin before resistance was seen.
Survival in the AML patients ranged from 11-150 days, and
11-97 weeks in CML patients. The non-haematological
toxicity was principally mild to moderate nausea and vomit-
ing and fatigue (in CML patients). Most patients were able
to take treatment at home, although only 1 AML patient did
not have to be admitted to hospital for supportive therapy.
Five of the CML patients were able to spend the majority of
their time at home, and two patients returned to work.
The results suggest that oral idarubicin can be a useful
drug for palliative treatment in CML blast crisis and in some
patients with resistant AML.
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